

09-26-01

09-26-01 PCT \$

JC20 Rec'd PCT/PTO SEP 25 2001

| | | |
|---|--|---|
| FORM PTO 101 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (MODIFIED) | | ATTORNEY'S DOCKET NUMBER X-12652 |
| TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 | | U.S. APPLICATION NO (if known, see 37 C.F.R. 1.5) 09/937636 |
| INTERNATIONAL APPLICATION NO. PCT/US00/06682 | INTERNATIONAL FILING DATE 03/22/2000 (03.22.00) | PRIORITY DATE CLAIMED 04/02/1999 (04.02.99) |
| TITLE OF INVENTION: hOB-BP2h COMPOSITIONS, METHODS AND USES THEREOF | | |
| APPLICANT(S) FOR DO/EO/US: Eric Wen Su, et al. | | |
| Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: | | |
| <ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none">a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).b. <input type="checkbox"/> has been transmitted by the International Bureau.c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))<ol style="list-style-type: none">a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).b. <input type="checkbox"/> have been transmitted by the International Bureau.c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input checked="" type="checkbox"/> have not been made and will not be made.8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).10. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an English language translation of the annexes to the IPER under PCT Article 36 (35 U.S.C. 371(c)(5)) <p>Items 11. to 16. below concern document(s) or information included:</p> <ol style="list-style-type: none">11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.15. <input type="checkbox"/> A substitute specification.16. <input type="checkbox"/> A change of power of attorney and/or address letter.16. <input type="checkbox"/> Other items or information: | | |

JC09 Rec'd PCT/PTO 2 5 SEP 2001

| | | | | | |
|--|-------------------------------------|---|-------------------|------------------------------|---------------------------|
| U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) | | INTERNATIONAL APPLICATION NO. | | ATTORNEY'S DOCKET NUMBER | |
| 09/937636 | | PCT/US00/06682 | | X-12652 | |
| 17. | <input checked="" type="checkbox"/> | The following fees are submitted: | | | CALCULATIONS PTO USE ONLY |
| BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1000.00 | | | | | |
| International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 | | | | | |
| International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$710.00 | | | | | |
| International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 | | | | | |
| International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$100.00 | | | | | |
| ENTER APPROPRIATE BASIC FEE AMOUNT = | | | | \$ 690.00 | |
| Surcharge of \$130.00 for furnishing the oath or declaration later than <u> 20 </u> <u> 30 </u> months from the earliest claimed priority date (37 CFR 1.492(e)). | | | | \$ | |
| CLAIMS | NUMBER FILED | NUMBER EXTRA | RATE | | |
| Total claims | 10 - 20= | | X \$18.00 | \$ | |
| Independent claims | 4 - 3= | 1 | X \$80.00 | \$ 80.00 | |
| MULTIPLE DEPENDENT CLAIM(S) (if applicable) | | | + \$270.00 | \$ | |
| TOTAL OF ABOVE CALCULATIONS = | | | | \$ 770.00 | |
| Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28). | | | | \$ | |
| SUBTOTAL = | | | | \$ 770.00 | |
| Processing fee of \$130.00 for furnishing English translation later than <u> 20 </u> <u> 30 </u> months from the earliest claimed priority date (37 CFR 1.492(f)). | | | | \$ | |
| TOTAL NATIONAL FEE = | | | | \$ 770.00 | |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property | | | | \$ | |
| TOTAL FEES ENCLOSED = | | | | \$ 770.00 | |
| | | | | Amount to be refunded | \$ |
| | | | | charged | \$ |
| a. | <input type="checkbox"/> | A check in the amount of \$_____ to cover the above fees is enclosed. | | | |
| b. | <input checked="" type="checkbox"/> | Please charge my Deposit Account No. 05-0840 in the amount of <u>\$ 770.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. | | | |
| c. | <input checked="" type="checkbox"/> | The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 05-0840 A duplicate copy of this sheet is enclosed. | | | |
| NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. | | | | | |
| SEND ALL CORRESPONDENCE TO: ELI LILLY AND COMPANY PATENT DIVISION/RS LILLY CORPORATE CENTER | | | | | |
| <div>September 24, 2001 Date</div> <div>Thomas G. Plant SIGNATURE</div> <div>Thomas G. Plant NAME</div> <div>35,784 REGISTRATION NUMBER</div> <div>(317) 276-5332 TELEPHONE NUMBER</div> | | | | | |



JC10 Rec'd PCT/PTO 05 MAR 2002

#5

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Arlington, VA 22202, on the date appearing below.

ELI LILLY AND COMPANY

By KS Rhoades

Date 2-26-02

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicants : Eric Wen Su and Jian-Jun Wei)
Serial No. : 09/937,636)
Filed : March 22, 2000)
For : HOB-BP2H COMPOSITIONS, METHODS)
AND USES THEREOF)
Docket No. : X-12652)

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 C.F.R. 1.821(f) (SEQUENCE LISTING)

Assistant Commissioner for Patents
Arlington, VA 22202
Sir:

I hereby affirm that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

Respectfully submitted,


Thomas E. LaGrandeur
Attorney/Agent for Applicants
Registration No. P51,026
Phone: 317-651-1527

Eli Lilly and Company
Patent Division/TEL
Lilly Corporate Center
Indianapolis, Indiana 46285

February 22, 2002

09/937636

JC09 Rec'd PCT/PTO 25 SEP 2001

| | |
|---|----------------------------------|
| "Express Mail" mailing label number <u>EL018701159US</u> | |
| Date of Deposit <u>Sept 25, 2001</u> | |
| I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231. | |
| <u>Olga M Frank</u> Printed Name | <u>Olga M Frank</u> Signature |

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Eric Wen Su and Jian-Jun Wei)
For : hOB-BP2h COMPOSITIONS, METHODS)
AND USES THEREOF)
Docket No. : X-12652)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents

Washington, D. C. 20231

Sir:

In the Claims

Please cancel claims 1-21 and add the following new claims 22-31.

22. An isolated hOB-BP2h nucleic acid comprising an hOB-BP2h polynucleotide encoding at least 90-100% of the contiguous amino acids as shown in SEQ ID NO:3.

23. An isolated hOB-BP2h nucleic acid comprising the complementary sequence of the nucleic acid of Claim 22.

24. A recombinant vector comprising at least one nucleic acid according to Claim 22.

25. A host cell comprising at least one recombinant vector according to Claim 24.

26. An isolated hOB-BP2h polypeptide comprising at least 90-100% of the contiguous amino acids as shown in SEQ ID NO:3.

27. The polypeptide of Claim 26 further comprising at least one mutation corresponding to at least one substitution, insertion or deletion selected from the group consisting of 3P, 4L, 8P, 9L, 11W, 15L, 16Q, 17E, 18K, 19P, 20V, 21Y, 22E, 23L, 24Q, 27K, 30T, 32Q, 37V, 38L, 47W, 48R, 49S, 51Y, 52S, 54P, 56L, 58V, 70A, 71E, 72V, 77N, 78P, 79D, 81R, 83K, 84P, 85E, 87Q, 91R, 93L, 96V, 97Q, 99K, 104S, 106G, 109R, 111E, 113T, 114G, 115S, 124R, 125D, 127K, 129S, 130Y, 131Q, 132Q, 133N, 134K, 135L, 136N, 138E, 141V, 143S, 143I, 144F, 144E, 145T, 210N, and 252A of SEQ ID NO:3.

28. An isolated hOB-BP2h nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 90% identical to a sequence selected from the group consisting of:

(a) a nucleotide sequence encoding a polypeptide comprising a portion of SEQ ID NO:3, wherein said portion lacks from 30 to 50 amino acids from the amino terminus of said complete amino acid sequence as in SEQ ID NO:3;

(b) a nucleotide sequence encoding a polypeptide comprising a portion of amino acid sequence of SEQ ID NO:3 wherein said portion lacks from 131 to 171 amino acids from the carboxy-terminus of said complete amino acid sequence as in SEQ ID NO:3; and

c) a nucleotide sequence encoding a polypeptide comprising a portion of the amino acid sequence of SEQ ID NO:3 wherein said portion includes a combination of any of the amino terminal and carboxy terminal deletions according to (a) and (b), above.

(a) the amino acid sequence of a full-length polypeptide having the complete amino acid sequence as in SEQ ID NO:3;

(a) the amino acid sequence of a full-length polypeptide having the complete amino acid sequence as in SEQ ID NO:3;

(b) the amino acid sequence comprising a portion of the complete amino acid sequence as in SEQ ID NO:3 wherein said portion lacks from 30-50 amino acids from the amino terminus of said complete amino acid sequence.

(c) the amino acid sequence comprising a portion of the complete amino acid sequence as in SEQ ID NO:3 wherein said portion lacks from 131-171 amino acids from the carboxy-terminus of said complete amino acid sequence.

(d) the amino acid sequence comprising a portion of the complete amino acid sequence as in SEQ ID NO:3 wherein said portion is the result of a combination of any of the amino-terminal and carboxy-terminal deletions according to (b) and (c), above.

30. The polypeptide of Claim 26 fused to a heterologous polypeptide.

31. The polypeptide of Claim 30 in which the heterologous polypeptide is a constant region of an immunoglobulin.

Remarks

It is respectfully submitted that entry of the amendment submitted herewith introduces no new matter to the application. Basis for the amended claims may be found throughout the specification as filed. A current set of all claims is attached herewith for the convenience of the Examiner.

Respectfully submitted,

Thomas G. Plant

Thomas G. Plant
Registration No. 35,784
Phone: 317-276-2459

Eli Lilly and Company
Patent Division/TGP
Lilly Corporate Center
Indianapolis, Indiana 46285

September 24, 2001

What is claimed is:

22. An isolated hOB-BP2h nucleic acid comprising an hOB-BP2h polynucleotide encoding at least 90-100% of the contiguous amino acids as shown in SEQ ID NO:3.

23. An isolated hOB-BP2h nucleic acid comprising the complementary sequence of the nucleic acid of Claim 22.

24. A recombinant vector comprising at least one nucleic acid according to Claim 22.

25. A host cell comprising at least one recombinant vector according to Claim 24.

26. An isolated hOB-BP2h polypeptide comprising at least 90-100% of the contiguous amino acids as shown in SEQ ID NO:3.

27. The polypeptide of Claim 26 further comprising at least one mutation corresponding to at least one substitution, insertion or deletion selected from the group consisting of 3P, 4L, 8P, 9L, 11W, 15L, 16Q, 17E, 18K, 19P, 20V, 21Y, 22E, 23L, 24Q, 27K, 30T, 32Q, 37V, 38L, 47W, 48R, 49S, 51Y, 52S, 54P, 56L, 58V, 70A, 71E, 72V, 77N, 78P, 79D, 81R, 83K, 84P, 85E, 87Q, 91R, 93L, 96V, 97Q, 99K, 104S, 106G, 109R, 111E, 113T, 114G, 115S, 124R, 125D, 127K, 129S, 130Y, 131Q, 132Q, 133N, 134K, 135L, 136N, 138E, 141V, 143S, 143I, 144F, 144E, 145T, 210N, and 252A of SEQ ID NO:3.

28. An isolated hOB-BP2h nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 90% identical to a sequence selected from the group consisting of:

(a) a nucleotide sequence encoding a polypeptide comprising a portion of SEQ ID NO:3, wherein said portion lacks from 30 to 50 amino acids from the amino terminus of said complete amino acid sequence as in SEQ ID NO:3;

(b) a nucleotide sequence encoding a polypeptide comprising a portion of amino acid sequence of SEQ ID NO:3 wherein said portion lacks from 131 to 171 amino acids from the carboxy-terminus of said complete amino acid sequence as in SEQ ID NO:3; and

c) a nucleotide sequence encoding a polypeptide comprising a portion of the amino acid sequence of SEQ ID NO:3 wherein said portion includes a combination of any of the amino terminal and carboxy terminal deletions according to (a) and (b), above.

29. An isolated polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of a full-length polypeptide having the complete amino acid sequence as in SEQ ID NO:3;

(b) the amino acid sequence comprising a portion of the complete amino acid sequence as in SEQ ID NO:3 wherein said portion lacks from 30-50 amino acids from the amino terminus of said complete amino acid sequence.


(c) the amino acid sequence comprising a portion of the complete amino acid sequence as in SEQ ID NO:3

wherein said portion lacks from 131-171 amino acids from the carboxy-terminus of said complete amino acid sequence.

(d) the amino acid sequence comprising a portion of the complete amino acid sequence as in SEQ ID NO:3 wherein said portion is the result of a combination of any of the amino-terminal and carboxy-terminal deletions according to (b) and (c), above.

30. The polypeptide of Claim 26 fused to a heterologous polypeptide.

31. The polypeptide of Claim 30 in which the heterologous polypeptide is a constant region of an immunoglobulin.



<110> Eric Wen Su
Jian-Jun Wei

<130> x12652

<141>

<170> PatentIn Ver. 2.1

<210> 1

| | |
|-----------------------|------|
| $\langle 210 \rangle$ | 1 |
| $\langle 211 \rangle$ | 1536 |

<212> DNA

<213> Homo sapiens

<400> 1

| | | | | | | |
|-------------|-------------|------------|------------|------------|-------------|------|
| atgctaactgc | cactgctgct | gtcctcgctg | ctgggcgggt | cccaggctat | ggatgggaga | 60 |
| ttctggatac | gagtgcagga | gtcagtgatg | gtgccggagg | gcctgtgcat | ctctgtgccc | 120 |
| tgctctttct | cctacccccg | acaggactgg | acagggtcta | ccccagctta | tggctactgg | 180 |
| ttcaaaagcag | tgactgagac | aaccaagggt | gtctctgtgg | ccacaaacca | ccagagtctga | 240 |
| gaggtggaaa | tgagcacccg | gggccgattc | cagctcactg | gggatcccg | caaggggaac | 300 |
| tgctccttgg | tgatcagaga | cgcgcagatg | caggatgagt | cacagtaact | ctttcgggtg | 360 |
| gagagaggaa | gctatgtgag | atataatttc | atgaacgatg | ggttctttct | aaaagtaaca | 420 |
| gccctgactc | agaagctctga | tgtctacatc | cccgagacc | tggagcccg | gcagccgggt | 480 |
| acggtcatct | gtgtgtttaa | ctgggccttt | gaggaatgtc | cacccccttc | tttctcttgg | 540 |
| acgggggctg | ccctctctct | ccaaggaacc | aaaccaacga | cctcccactt | ctcagtgtct | 600 |
| agcttcacgc | ccagacccca | ggaccacgac | accgacctca | cctgccatgt | ggactttctc | 660 |
| agaaagggtg | tgagcgaca | gaggaccgtc | cgactccgtg | tggcctatgc | ccccagagac | 720 |
| cttgttatca | gcatttcacg | tgacaacacg | ccagatcctc | cagagaacct | gagagtgatg | 780 |
| gtttcccaag | caaacaggac | agtcttgga | aaccttgga | acggcacgtc | tctcccagta | 840 |
| ctggagggcc | aaagcctgtg | cctggctctg | gtcacacaca | gcagccccc | agccaggctg | 900 |
| agctggacc | agaggggaca | ggttctgagc | ccctccagc | cctcagaccc | cggggtcctg | 960 |
| gagctgcctc | gggttcaagt | ggagcacga | ggagagttca | cctgccacgc | tcggcaccca | 1020 |
| ctgggtctcc | agcacgtctc | tctcagcctc | tccgtgcact | ataagaagg | actcatctca | 1080 |
| acggcattct | ccaatggagc | gtttctggga | atcggcatca | cggctcttct | tttctctctg | 1140 |
| ctggccctga | tcatcatgaa | gattctaccg | aagagacgga | ctcagacaga | aaccccagg | 1200 |
| cccaggttct | ccggcacag | cacgatcctg | gattacatca | atgtggtccc | gacggctggc | 1260 |
| cccttggtct | agaagcgga | tcagaaagcc | acaccaaaca | gtcctcggac | ccctcttcca | 1320 |
| ccaggtgctc | cctcccaga | atcaaagaag | aaccagaaaa | agcagtatca | gttgcccagt | 1380 |
| ttcccagaac | ccaatcatc | cactcaagcc | ccagaatccc | aggagagcca | agaggagctc | 1440 |
| cattatgcca | cgtcaactt | cccaggcgtc | agacccaggc | ctgaggcccc | gatgcccaag | 1500 |
| ggcaccacag | ggattatgc | agaagtcaag | ttccaa | | | 1536 |

 $\langle 210 \rangle$ 2

<211> 1917

<212> DNA

<213> Homo sapiens

<400> 2

| | | | | | | |
|-------------|------------|------------|------------|------------|------------|-----|
| atgctactgc | cactgctgct | gtcctcgctg | ctgggagggt | cccaggctat | ggatgggaga | 60 |
| ttctggatac | gagtgccagg | gtcagctgat | gtgcgggtag | gcctgtgcat | ctctgtgccc | 120 |
| tgctctttct | cctaccctcc | acaagactgg | acagggtgta | ccccagctta | tggctactgg | 180 |
| ttcaaaagcag | tgactgagac | aaccaagggt | gctcctgtgg | ccacaaacca | ccagagtcga | 240 |
| gagggtggaaa | tgagcacccc | gggcgcattc | cagctcactg | gggattcccg | caagggaac | 300 |
| tgtctcttgg | tgatcacaga | cgccagatg | caggatgagt | cacagactct | cttccgggtg | 360 |
| gagagaggaa | gctatgtgag | atataatttc | atgaacgatg | ggttctttct | aaaagtaaca | 420 |

X-12652 Seqlist.txt

```

165                               170                               175
Ser Phe Ser Trp Thr Gly Ala Ala Leu Ser Ser Gln Gly Thr Lys Pro
180                               185                               190
Thr Thr Ser His Phe Ser Val Leu Ser Phe Thr Pro Arg Pro Gln Asp
195
His Asp Thr Asp Leu Thr Cys His Val Asp Phe Ser Arg Lys Gly Val
210                               215                               220
Ser Ala Gln Arg Thr Val Arg Leu Arg Val Ala Tyr Ala Pro Arg Asp
225                               230                               235
Leu Val Ile Ser Ile Ser Arg Asp Asn Thr Pro Asp Pro Pro Glu Asn
245                               250                               255
Leu Arg Val Met Val Ser Gln Ala Asn Arg Thr Val Leu Glu Asn Leu
260                               265                               270
Gly Asn Gly Thr Ser Leu Pro Val Leu Glu Gly Gln Ser Leu Cys Leu
275                               280                               285
Val Cys Val Thr His Ser Ser Pro Pro Ala Arg Leu Ser Trp Thr Gln
290                               295                               300
Arg Gly Gln Val Leu Ser Pro Ser Gln Pro Ser Asp Pro Gly Val Leu
305                               310                               315
Glu Leu Pro Arg Val Gln Val Glu His Glu Gly Glu Phe Thr Cys His
325                               330                               335
Ala Arg His Pro Leu Gly Ser Gln His Val Ser Leu Ser Leu Ser Val
340                               345                               350
His Tyr Lys Lys Gly Leu Ile Ser Thr Ala Phe Ser Asn Gly Ala Phe
355                               360                               365
Leu Gly Ile Gly Ile Thr Ala Leu Leu Phe Leu Cys Leu Ala Leu Ile
370                               375                               380
Ile Met Lys Ile Leu Pro Lys Arg Arg Thr Gln Thr Glu Thr Pro Arg
385                               390                               395
Pro Arg Phe Ser Arg His Ser Thr Ile Leu Asp Tyr Ile Asn Val Val
405                               410                               415
Pro Thr Ala Gly Pro Leu Ala Gln Lys Arg Asn Gln Lys Ala Thr Pro
420                               425                               430
Asn Ser Pro Arg Thr Pro Leu Pro Pro Gly Ala Pro Ser Pro Glu Ser
435                               440                               445
Lys Lys Asn Gln Lys Lys Gln Tyr Gln Leu Pro Ser Phe Pro Glu Pro
450                               455                               460
Lys Ser Ser Thr Gln Ala Pro Glu Ser Gln Glu Ser Gln Glu Glu Leu
465                               470                               475                               480
His Tyr Ala Thr Leu Asn Phe Pro Gly Val Arg Pro Arg Pro Glu Ala
485                               490                               495
Arg Met Pro Lys Gly Thr Gln Ala Asp Tyr Ala Glu Val Lys Phe Gln
500                               505                               510

```

x-12652 Seqlist.txt

<210> 4
 <211> 639
 <212> PRT
 <213> Homo sapiens

<400> 4
 Met Leu Leu Pro Leu Leu Leu Ser Ser Leu Leu Gly Gly Ser Gln Ala
 1 5 10 15
 Met Asp Gly Arg Phe Trp Ile Arg Val Gln Glu Ser Val Met Val Pro
 20 25 30
 Glu Gly Leu Cys Ile Ser Val Pro Cys Ser Phe Ser Tyr Pro Arg Gln
 35 40 45
 Asp Trp Thr Gly Ser Thr Pro Ala Tyr Gly Tyr Trp Phe Lys Ala Val
 50 55 60
 Thr Glu Thr Thr Lys Gly Ala Pro Val Ala Thr Asn His Gln Ser Arg
 65 70 75 80
 Glu Val Glu Met Ser Thr Arg Gly Arg Phe Gln Leu Thr Gly Asp Pro
 85 90 95
 Ala Lys Gly Asn Cys Ser Leu Val Ile Arg Asp Ala Gln Met Gln Asp
 100 105 110
 Glu Ser Gln Tyr Phe Phe Arg Val Glu Arg Gly Ser Tyr Val Arg Tyr
 115 120 125
 Asn Phe Met Asn Asp Gly Phe Phe Leu Lys Val Thr Val Leu Ser Phe
 130 135 140
 Thr Pro Arg Pro Gln Asp His Asn Thr Asp Leu Thr Cys His Val Asp
 145 150 155 160
 Phe Ser Arg Lys Gly Val Ser Ala Gln Arg Thr Val Arg Leu Arg Val
 165 170 175
 Ala Tyr Ala Pro Arg Asp Leu Val Ile Ser Ile Ser Arg Asp Asn Thr
 180 185 190
 Pro Ala Leu Glu Pro Gln Pro Gln Gly Asn Val Pro Tyr Leu Glu Ala
 195 200 205
 Gln Lys Gly Gln Phe Leu Arg Leu Leu Cys Ala Ala Asp Ser Gln Pro
 210 215 220
 Pro Ala Thr Leu Ser Trp Val Leu Gln Asn Arg Val Leu Ser Ser Ser
 225 230 235 240
 His Pro Trp Gly Pro Arg Pro Leu Gly Leu Glu Leu Pro Gly Val Lys
 245 250 255
 Ala Gly Asp Ser Gly Arg Tyr Thr Cys Arg Ala Glu Asn Arg Leu Gly
 260 265 270
 Ser Gln Gln Arg Ala Leu Asp Leu Ser Val Gln Tyr Pro Pro Glu Asn
 275 280 285

$\frac{1}{\sqrt{\pi}} \int_{-\infty}^{\infty} f(x) \delta(x-a) dx = f(a)$

-1-

hOB-BP2h COMPOSITIONS, METHODS AND USES THEREOF**BACKGROUND OF THE INVENTION****FIELD OF THE INVENTION**

5 The present invention relates to compounds and compositions comprising novel human obesity protein binding protein-2 homolog (hOB-BP2h) polypeptides, nucleic acids, host cells, transgenics, chimerics, antibodies, compositions, and methods of making and using thereof.

10 RELATED ART

Obesity, and especially upper body obesity, is a common and very serious public health problem in the United States and throughout the world, and is expected to worsen as the population ages. Currently, about 33% of Americans are
15 overweight enough to be unhealthy (i.e., body weight greater than 26 percent above standard weight guidelines). The proportion of obese adults among the well-fed populations of the world is expected to rise to more than 50% within 20 years.

20 Numerous studies indicate that lowering body weight dramatically reduces risk for chronic diseases such as diabetes, hypertension, hyperlipidemia, coronary heart disease, cancer, and musculoskeletal diseases. Recent estimates for the medical cost of obesity are 150 billion
25 dollars (\$US) world-wide. Although the precise cause of obesity is not known, obese patients may lose weight through deliberate modification of behavior, such as changing diet and increasing exercise. Unfortunately, an estimated 33 billion dollars (\$US) are spent each year on such weight-
30 loss measures that are largely futile, with failure rates reaching 95%. Failure may be due to genetic factors that cause increased appetite, a preference for high-fat foods,

-2-

or a tendency for lipogenic metabolism. People inheriting such genetic traits are prone to becoming obese regardless of their efforts to combat the condition. Therefore, a pharmacological agent that can correct this adiposity handicap and allow the physician to successfully treat obese patients in spite of their genetic inheritance is needed.

The obesity gene (Ob gene) has been demonstrated to encode a protein, termed leptin, which appears to decrease appetite and control energy metabolism. Studies have shown mice deficient in active Ob gene product or carrying an Ob gene mutation (ob/ob) are grossly obese and develop diabetes mellitus, while injection of leptin causes the mice to curb their food intake and shed fat. See, e.g., Barinaga (1995) Science 269:475-476; Zhang, et al. (1994) Nature 372:425-432; Pelleymounter, et al. (1995) Science 269:540-543; Halaas, et al. (1995) Science 269:543-546.

Leptin is primarily secreted by adipose tissue, and is thought to exert its effects by interactions with specific receptors, e.g., in the hypothalamus. In humans, circulating leptin levels are increased in obesity and regulated by fasting, feeding, and body weight changes.

Unfortunately, the obesity protein disclosed by Zhang et al. and other obesity proteins and analogs subsequently disclosed by others are poor pharmaceutical agents for two reasons: they have a short half-life in the circulation [about 25 minutes; Klein, S., et al., Diabetes 45:984-987 (1996)]; and they are unstable in solution formulations, especially physically unstable.

In blood, leptin is thought to be bound to other proteins. See, e.g., Houseknecht, et al. (1996) Diabetes 45:1638-1643; Sinha, et al. (1996) J. of Clin. Invest. 98:1277-1282; Diamond, et al. (1997) Biochem. Biophys. Res. Comm. 233:818-822. Modulating binding protein systems are known to exist for numerous circulating hormones, growth

-3-

factors, and cytokines including steroid and thyroid hormones, TGF β 1, TGF β 2, TNF α , IGF-1, and IGF-II. See Bonner, J.C., and Brody, A.R. (1995) Am. J. Physiol. 268:L869-L878. These binding proteins often serve to alter the clearance rate of hormones or cytokines, increase or decrease the biological activity of the ligand, and provide responsiveness to previously unresponsive cells. Leptin binding proteins in blood could similarly serve to modulate the active form of leptin.

Generally, hormone action depends on the interaction of soluble hormone with receptor proteins expressed by responsive cells. The classical concepts of hormone action considered the hormone or humoral "liquid" factor to be mobile in body fluids and the receptors to be fixed to cells. However, over the past several years many receptors have been found to have soluble isoforms in addition to the membrane-bound forms that are traditionally thought of as the mediators of ligand-induced signal transduction. Receptors for growth hormone, G-CSF, GM-CSF, IL-4, IL-5, IL-6, IL-7, leukemia inhibitory factor (LIF), and ciliary neurotropic factor (CNTF) in the hematopoietin superfamily, as well as IL-1, IL-2, (IL-2 receptor ?), tumor necrosis factor (TNF), M-CSF/CSF-1, EGF, and NGF have been isolated either as soluble proteins or as alternatively processed forms that are predicted on the basis of their cDNA sequence to encode soluble receptors. The soluble isoforms of G-CSF, GM-CSF, IL-4, IL-5, IL-7, and LIF receptors appear to arise as a result of alternative mRNA splicing. The soluble IL-1, IL-2R, and TNF receptors appear to be released from the cell surface by proteolytic cleavage of the extracellular domains of the membrane-associated receptors.

There are indications that soluble receptors have physiologic and pathologic significance. Elevated serum

-4-

levels of soluble TNF receptor are evident in some patients with hairy cell leukemia and chronic lymphocytic leukemia, and soluble IL-2R is seen in the serum and ascites of some patients with ovarian cancer.

5 The physiologic roles of the soluble receptors are incompletely understood. Some soluble receptors act as serum binding proteins and are believed to stabilize their ligands (hormone). They are thought to have no intrinsic
10 role in signal transduction and only function to prevent degradation of their ligand until it is delivered to the membrane-associated receptor. Soluble receptors can also compete with their membrane-bound counterparts for binding to ligand. Thus, in the presence of sufficient amounts of soluble receptor, ligand binding to the membrane-associated
15 receptor is diminished and signaling is dampened or inhibited. In this scenario, the soluble receptor "modulates" concentrations of active ligand in the extracellular milieu.

 The action of membrane-associated ligands when
20 contrasted with that of signal-altering soluble receptors blurs the distinction between what comprises a receptor and what comprises a ligand. Furthermore, soluble receptors may be generated in the laboratory even from receptors that do not express a native soluble isoform. The construction and
25 development of soluble receptors as pharmaceuticals may be useful to specifically inhibit or facilitate hormone action in disease states.

 Because of the desire to provide a more effective pharmaceutical treatment of the severe problem of obesity,
30 there exists a need to isolate and provide leptin binding proteins that may effectively increase the plasma half-life of circulating obesity protein, improve the physical stability of obesity protein formulations, or act

-5-

independently to provide a more suitable treatment for obesity. Accordingly, the present invention provides hOB-BP2h polypeptides, nucleic acids, host cells, transgenics, chimerics, as well as methods of making and
5 using thereof.

SUMMARY OF THE INVENTION

The present invention provides isolated nucleic acids and encoded hOB-BP2h polypeptides, including specified
10 fragments and variants thereof, as well as hOB-BP2h compositions, probes, primers, vectors, host cells, antibodies, transgenics, chimerics and methods of making and using thereof, as described and enabled herein.

The present invention provides, in one aspect, isolated
15 nucleic acid molecules comprising or complementary to a polynucleotide encoding specific hOB-BP2h polypeptides, as well as fragments or specified variants comprising at least one domain thereof.

Such polypeptides are provided as non-limiting examples
20 by the corresponding domains, specified fragments, and specified variants of hOB-BP2h polypeptides corresponding to at least 90-100% of the contiguous amino acids of at least one of SEQ ID NO:3, 4, or 5.

The present invention further provides recombinant
25 vectors, comprising 1-40 of said isolated hOB-BP2h nucleic acid molecules of the present invention, host cells containing such nucleic acids and recombinant vectors, as well as methods of making and using such nucleic acid, vectors and host cells.

30 The present invention also provides methods of making or using such nucleic acids, vectors and host cells, such as but not limited to, using them for the production of hOB-BP2h nucleic acids and polypeptides by known recombinant,

-6-

synthetic and purification techniques, based on the teaching and guidance presented herein in combination with what is known in the art.

The present invention also provides an isolated hOB-
5 BP2h polypeptide, comprising at least one fragment, domain or specified variant of at least 90-100% of the contiguous amino acids of at least one portion of at least one of SEQ ID NO:3, 4, or 5.

The present invention also provides an isolated hOB-
10 BP2h polypeptide as described herein, wherein the polypeptide further comprises at least one specified substitution, insertion or deletion corresponding to portions or residues of at least one of SEQ ID NO:3, 4, or 5.

15 The present invention also provides an isolated hOB-BP2h polypeptide as described herein, wherein the polypeptide has at least one activity, such as, but not limited to, leptin binding, weight loss, and regulation of adiposity (Reitman, et al. (1997) Journal of Biological
20 Chemistry, 272:(48):30546-30551; Halaas, et al. (1995) Science, 269:540-542; Pellymounter, et al. (1995) Science 269:540-543). A hOB-BP2h polypeptide can thus be screened for a corresponding activity according to known methods.

The present invention also provides a composition
25 comprising an isolated hOB-BP2h nucleic acid and polypeptide as described herein and a carrier or diluent. The carrier or diluent can optionally be pharmaceutically acceptable, according to known methods.

The present invention also provides an isolated nucleic
30 acid probe, primer or fragment, as described herein, wherein the nucleic acid comprises a polynucleotide of at least 10 nucleotides, corresponding or complementary to at least 10 nucleotides of at least one of SEQ ID NO:1, SEQ ID NO:2, or a consensus sequence thereof.

-7-

The present invention also provides a recombinant vector comprising an isolated hOB-BP2h nucleic acid as described herein.

The present invention also provides a host cell,
5 comprising an isolated hOB-BP2h nucleic acid as described herein.

The present invention also provides a method for constructing a recombinant host cell that expresses a hOB-BP2h polypeptide, comprising introducing into the host cell
10 a hOB-BP2h nucleic acid in replicatable form as described herein to provide the recombinant host cell. The present invention also provides a recombinant host cell provided by a method as described herein.

The present invention also provides a method for
15 expressing at least one hOB-BP2h polypeptide in a recombinant host cell, comprising culturing a recombinant host cell as described herein under conditions wherein at least one hOB-BP2h polypeptide is expressed in detectable or recoverable amounts.

20 The present invention also provides an isolated hOB-BP2h polypeptide produced by a recombinant, synthetic, and any suitable purification method as described herein and as known in the art.

The present invention also provides a pharmaceutical
25 formulation containing as an active ingredient a hOB-BP2h polypeptide and/or nucleic acid composition as described herein.

Furthermore, the present invention provides a method of treating obesity or obesity related diseases by
30 administering a pharmaceutical formulation of the compounds and/or compositions of the present invention. Such methods of treating obesity or obesity related disorders are well within the skill of an ordinarily skilled artisan provided the inventions disclosed herein. An example of such

-8-

knowledge in the art includes, but is not limited to, PCT Publication No. 98/06752 which is entirely incorporated by reference herein.

5 The present invention also provides a hOB-BP2h antibody or fragment, comprising a polyclonal and monoclonal antibody or fragment that specifically binds at least one epitope specific to at least one hOB-BP2h polypeptide as described herein.

10 The present invention also provides a method for producing a hOB-BP2h antibody or antibody fragment, comprising generating the antibody or fragment that binds at least one epitope that is specific to an isolated hOB-BP2h polypeptide as described herein, the generating done by known recombinant, synthetic and hybridoma methods.

15 The present invention also provides a hOB-BP2h antibody or fragment produced by a method as described herein or as known in the art.

The present invention also provides a method for identifying compounds that bind a hOB-BP2h polypeptide, 20 comprising

a) admixing at least one isolated hOB-BP2h polypeptide as described herein with a test compound or composition; and

25 b) detecting at least one binding interaction between the polypeptide and the compound or composition, optionally further comprising detecting a change in biological activity, such as a reduction or increase.

DESCRIPTION OF THE INVENTION

30 The present invention provides isolated, recombinant and synthetic nucleic acid molecules comprising at least one polynucleotide encoding at least one hOB-BP2h polypeptide comprising specific full length sequences, fragments and specified variants thereof, such polypeptides, and methods

-9-

of making and using said nucleic acids and polypeptides thereof. A hOB-BP2h polypeptide of the invention comprises at least one fragment, domain, and specified variant as a portion or fragment of a hOB-BP2h protein as described
5 herein.

Utility

The present invention also provides at least one utility by providing isolated nucleic acid comprising polynucleotides of sufficient length and complementarity to a hOB-BP2h
10 nucleic acid for use as probes or amplification primers in the detection, quantitation, or isolation of gene sequences or transcripts. For example, isolated nucleic acids of the present invention can be used as probes for detecting deficiencies in the level of mRNA, in screens for detection
15 of mutations in at least one hOB-BP2h gene (e.g., substitutions, deletions, or additions), or for monitoring up-regulation of expression of said gene, or changes in biological activity as described herein in screening assays of compounds, and for detection of any number of allelic
20 variants (polymorphisms or isoforms) of the gene.

The isolated nucleic acids of the present invention can also be used for recombinant expression of hOB-BP2h polypeptides, or for use as immunogens in the preparation and screening of antibodies. The isolated nucleic acids of the
25 present invention can also be employed for use in sense or antisense suppression of one or more hOB-BP2h genes or nucleic acids, in a host cell, or tissue *in vivo* or *in vitro*.

Attachment of chemical agents which bind, intercalate, cleave and crosslink to the isolated nucleic acids of the
30 present invention can also be used to modulate transcription or translation of at least one nucleic acid disclosed herein.

-10-

Citations

All publications or patents cited herein are entirely incorporated herein by reference as they show the state of the art at the time of the present invention to provide

5 description and enablement of the present invention. Publications refer to scientific, patent publication or any other information available in any media format, including all recorded, electronic or printed formats. The following citations are entirely incorporated by reference: Ausubel, et al., eds., Current Protocols in Molecular Biology, John Wiley & Sons, N.Y., N.Y. (1987-1998); Coligan et al., eds., Current Protocols in Protein Science, John Wiley & Sons, Inc., N.Y., N.Y. (1995-1999); Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor, N.Y. (1989); Harlow and Lane, Antibodies, a Laboratory Manual, Cold Spring Harbor, N.Y. (1989); Coligan, et al., eds., Current Protocols in Immunology, John Wiley & Sons, N.Y., N.Y. (1992-1999).

Definitions

20 The following definitions of terms are intended to correspond to those as well known in the art. The following terms are therefore not limited to the definitions given, but are used according to the state of the art, as demonstrated by cited and contemporary publications or

25 patents.

A "polynucleotide" comprises at least 10-20 nucleotides of a nucleic acid (RNA, DNA or combination thereof), provided by any means, such as synthetic, recombinant isolation or purification method steps.

30 The terms "complementary" or "complementarity" as used herein refer to the capacity of purine, pyrimidine, synthetic or modified nucleotides to associate by partial or complete complementarity through hydrogen or other bonding

-11-

to form partial or complete double- or triple-stranded nucleic acid molecules. The following base pairs occur by complete complementarity: (i) guanine (G) and cytosine (C); (ii) adenine (A) and thymine (T); and adenine (A) and uracil (U). "Partial complementarity" refers to association of two or more bases by one or more hydrogen bonds or attraction that is less than the complete complementarity as described above. Partial or complete complementarity can occur between any two nucleotides, including naturally occurring or modified bases, e.g., as listed in 37 CFR § 1.822. All such nucleotides are included in polynucleotides of the invention as described herein.

The term "fusion protein" denotes a hybrid protein molecule not found in nature comprising a translational fusion or enzymatic fusion in which two or more different proteins or fragments thereof are covalently linked on a single polypeptide chain. The term "polypeptide" also includes such fusion proteins.

"Host cell" refers to any eucaryotic, procaryotic, or fusion or other cell or pseudo cell or membrane-containing construct that is suitable for propagating and expressing an isolated nucleic acid that is introduced into a host cell by any suitable means known in the art (e.g., but not limited to, transformation or transfection, or the like), or induced to express an endogenous nucleic acid encoding a hOB-BP2h polypeptide according to the present invention. The cell can be part of a tissue or organism, isolated in culture or in any other suitable form.

The term "hybridization" as used herein refers to a process in which a partially or completely single-stranded nucleic acid molecule joins with a complementary strand through nucleotide base pairing. Hybridization can occur under conditions of low, moderate or high stringency, with high stringency preferred. The degree of hybridization

-12-

depends upon, for example, the degree of homology, the stringency conditions, and the length of hybridizing strands as known in the art.

By "isolated" nucleic acid molecule(s) is intended a
5 nucleic acid molecule, DNA, RNA, or both which has been removed from its native or naturally occurring environment. For example, recombinant nucleic acid molecules contained or generated in culture, a vector and a host cell are considered isolated for the purposes of the present
10 invention. Further examples of isolated nucleic acid molecules include recombinant nucleic acid molecules maintained in heterologous host cells or purified (partially or substantially) nucleic acid molecules in solution. Isolated RNA molecules include in vivo or in vitro RNA
15 transcripts of the nucleic acid molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically, purified from or provided in cells containing such nucleic acids, where the nucleic acid exists in other
20 than a naturally occurring form, quantitatively or qualitatively.

"Isolated" used in reference to at least one polypeptide of the invention describes a state of isolation such that the peptide or polypeptide is not in a naturally
25 occurring form and has been purified to remove at least some portion of cellular or non-cellular molecules with which the protein is naturally associated. However, "isolated" may include the addition of other functional or structural polypeptides for a specific purpose, where the other peptide
30 may occur naturally associated with at least one polypeptide of the present invention, but for which the resulting compound or composition does not exist naturally.

The term "mature protein" or "mature polypeptide" as used herein refers to the form(s) of the protein produced by

-13-

expression in a mammalian cell. It is generally hypothesized that once export of a growing protein chain across the rough endoplasmic reticulum has been initiated, proteins secreted by mammalian cells have a signal peptide (SP) sequence which is cleaved from the complete polypeptide to produce a "mature" form of the protein. Oftentimes, cleavage of a secreted protein is not uniform and may result in more than one species of mature protein. The cleavage site of a secreted protein is determined by the primary amino acid sequence of the complete protein and generally can not be predicted with complete accuracy.

Methods for predicting whether a protein has a SP sequence, as well as the cleavage point for that sequence, are available. The analysis of the amino acid sequence of the proteins described herein indicated the cleavage point is after amino acid 30-50, preferably between 40 and 41, as presented in SEQ ID NOS:3 or 4. The resulting mature proteins are presented as non-limiting examples. As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty.

Accordingly, the present invention provides polypeptides having a sequence of 90-100% of the contiguous sequence shown in SEQ ID NO: 3 and SEQ ID NO:4 which have an N-terminus beginning within 10 residues (i.e., + or - 10 residues) of the predicted cleavage point of SEQ ID NO:3 or 4. However, cleavage sites for a secreted protein may be determined experimentally by amino-terminal sequencing of the one or more species of mature proteins found within a purified preparation of the protein.

A "nucleic acid probe," "oligonucleotide probe," or "probe" as used herein comprises at least one detectably labeled or unlabeled nucleic acid which hybridizes under specified hybridization conditions with at least one other

-14-

nucleic acid. This term also refers to a single- or partially double-stranded nucleic acid, oligonucleotide or polynucleotide that will associate with a complementary or partially complementary target nucleic acid to form at least
5 a partially double-stranded nucleic acid molecule. A nucleic acid probe may be an oligonucleotide or a nucleotide polymer. A probe can optionally contain a detectable moiety which may be attached to the end(s) of the probe or be internal to the sequence of the probe, termed a "detectable
10 probe" or "detectable nucleic acid probe."

A "primer" is a nucleic acid fragment or oligonucleotide which functions as an initiating substrate for enzymatic or synthetic elongation of, for example, a nucleic acid molecule, e.g., using an amplification
15 reaction, such as, but not limited to, a polymerase chain reaction (PCR), as known in the art.

The term "stringency" refers to hybridization conditions for nucleic acids in solution. High stringency conditions disfavor non-homologous base pairing. Low
20 stringency conditions have much less of this effect. Stringency may be altered, for example, by changes in temperature and salt concentration, or other conditions, as well known in the art.

A non-limiting example of "high stringency" conditions
25 includes, for example, (a) a temperature of about 42 °C , a formamide concentration of about $\leq 20\%$, and a low salt (SSC) concentration, or, alternatively, a temperature of about 65°C, or less, and a low salt (SSPE) concentration; (b) hybridization in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate
30 (SDS), 1 mM EDTA at 65 °C (See, e.g., Ausubel, et al., ed., Current Protocols in Molecular Biology, 1987-1998, Wiley Interscience, New York, at §2.10.3). "SSC" comprises a hybridization and wash solution. A stock 20X SSC solution

-15-

contains 3M sodium chloride, 0.3M sodium citrate, pH 7.0. "SSPE" comprises a hybridization and wash solution. A 1X SSPE solution contains 180 mM NaCl, 9mM Na₂HPO₄, 0.9 mM NaH₂PO₄ and 1 mM EDTA, pH 7.4.

5 The term "vector" as used herein refers to a nucleic acid compound used for introducing exogenous or endogenous nucleic acid into host cells. A vector comprises a nucleotide sequence which may encode one or more polypeptide molecules. Plasmids, cosmids, viruses and bacteriophages,
10 in a natural state or which have undergone recombinant engineering, are non-limiting examples of commonly used vectors to provide recombinant vectors comprising at least one desired isolated nucleic acid molecule.

15 **Nucleic Acid Molecules**

Using the information provided herein, such as the nucleotide sequences encoding at least 90-100% of the contiguous amino acids of at least one of SEQ ID NO:3, SEQ ID NO:4, specified fragments or variants thereof, or a
20 deposited vector comprising at least one of these sequences, a nucleic acid molecule of the present invention encoding a hOB-BP2h polypeptide can be obtained using well-known methods.

Nucleic acid molecules of the present invention can be
25 in the form of RNA, such as mRNA, hnRNA, tRNA or any other form, or in the form of DNA, including, but not limited to, cDNA and genomic DNA obtained by cloning or produced synthetically, or any combination thereof. The DNA can be triple-stranded, double-stranded or single-stranded, or any
30 combination thereof. Any portion of at least one strand of the DNA or RNA can be the coding strand, also known as the sense strand, or it can be the non-coding strand, also referred to as the anti-sense strand.

-16-

Isolated nucleic acid molecules of the present invention include nucleic acid molecules comprising an open reading frame (ORF) shown in at least one of SEQ ID NO:1 and SEQ ID NO:2; nucleic acid molecules comprising the coding
5 sequence for a hOB-BP2h polypeptide, and nucleic acid molecules which comprise a nucleotide sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode at least one hOB-BP2h polypeptide as described herein. Of course, the
10 genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate such degenerate nucleic acid variants that code for specific hOB-BP2h polypeptides of the present invention. See, e.g., Ausubel, et al., *supra*, and such nucleic acid variants are
15 included in the present invention.

In another aspect, the invention provides isolated nucleic acid molecules encoding a hOB-BP2h polypeptide having an amino acid sequence as encoded by the cDNA clone contained in the plasmid deposited as designated clone names
20 _____ and ATCC Deposit Nos. _____, respectively, deposited on _____.

In a further embodiment, nucleic acid molecules are provided encoding the mature hOB-BP2h polypeptide or the
25 full-length hOB-BP2h polypeptide lacking the N-terminal methionine. The invention also provides an isolated nucleic acid molecule having the nucleotide sequence shown in at least one of SEQ ID NO:1, SEQ ID NO:2, the nucleotide sequence of an hOB-BP2h cDNA contained in at least one of
30 the above-described deposited clones listed herein, or a nucleic acid molecule having a sequence complementary thereto. Such isolated molecules, particularly nucleic acid molecules, are useful as probes for gene mapping by in situ hybridization with chromosomes, and for detecting

-17-

transcription, translation and expression of the hOB-BP2h gene in human tissue, for instance, by Northern blot analysis for mRNA detection.

Unless otherwise indicated, all nucleotide sequences
5 identified by sequencing a nucleic acid molecule herein can be or were identified using an automated nucleic acid sequencer, and all amino acid sequences of polypeptides encoded by nucleic acid molecules identified herein can be or were identified by codon correspondence or by translation
10 of a nucleic acid sequence identified using method steps as described herein or as known in the art. Therefore, as is well known in the art that for any nucleic acid sequence identified by this automated approach, any nucleotide sequence identified herein may contain some errors which are
15 reproducibly correctable by resequencing based upon an available or a deposited vector or host cell containing the nucleic acid molecule using well-known methods.

Nucleotide sequences identified by automation are typically at least about 95% to at least about 99.999%
20 identical to the actual nucleotide sequence of the sequenced nucleic acid molecule. The actual sequence can be more precisely identified by other approaches including manual nucleic acid sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in
25 an identified nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the identified amino acid sequence encoded by an identified nucleotide sequence will be completely different from the amino acid sequence
30 actually encoded by the sequenced nucleic acid molecule, beginning at the point of such an insertion or deletion.

-18-

Nucleic Acid Fragments

The present invention is further directed to fragments of the isolated nucleic acid molecules described herein. By a fragment of an isolated nucleic acid molecule is meant a molecule having at least 10 nucleotides of a nucleotide sequence of a deposited cDNA or a nucleotide sequence shown in at least one of SEQ ID NO:1 and SEQ ID NO:2, and is intended to mean fragments at least about 10 nucleotides, and at least about 40 nucleotides in length, which are useful, *inter alia* as diagnostic probes and primers as described herein. Of course, larger fragments such as at least about 50, 100, 120, 200, 500, 1000, 1500, and 2000 in length, are also useful according to the present invention as are fragments corresponding to most, if not all, of the nucleotide sequence (or the deposited cDNA) as shown in at least one of SEQ ID NO:1 or SEQ ID NO:2. By a fragment at least 10 nucleotides in length, for example, is intended fragments which include 10 or more contiguous nucleotides from the nucleotide sequence of the deposited cDNA or the nucleotide sequence as shown in SEQ ID NO:1, SEQ ID NO:2, or consensus sequences thereof, as determined by methods known in the art (See e.g., Ausubel, *supra*, Chapter 7).

Such nucleotide fragments are useful according to the present invention for screening DNA sequences that code for one or more fragments of a hOB-BP2h polypeptide as described herein. Such screening, as a non-limiting example can include the use of so-called "DNA chips" for screening DNA sequences of the present invention of varying lengths, as described, e.g., in U.S. Patent Nos. 5,631,734, 5,624,711, 5,744,305, 5,770,456, 5,770,722, 5,675,443, 5,695,940, 5,710,000, 5,733,729, which are entirely incorporated herein by reference.

-19-

As indicated, nucleic acid molecules of the present invention which comprise a nucleic acid encoding a hOB-BP2h polypeptide can include, but are not limited to, those encoding the amino acid sequence of the mature polypeptide, by itself; the coding sequence for the mature polypeptide and additional sequences, such as the coding sequence of at least one signal leader or fusion peptide or of the mature polypeptide, with or without the aforementioned additional coding sequences, such as at least one intron, together with additional, non-coding sequences, including but not limited to, introns and non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences that play a role in transcription, mRNA processing, including splicing and polyadenylation signals (for example - ribosome binding and stability of mRNA); an additional coding sequence which codes for additional amino acids, such as those which provide additional functionalities. Thus, the sequence encoding a polypeptide can be fused to a marker sequence, such as a sequence encoding a peptide that facilitates purification of the fused polypeptide.

Preferred nucleic acid fragments of the present invention also include nucleic acid molecules encoding epitope-bearing portions of a hOB-BP2h polypeptide.

25 Oligonucleotide and Polynucleotide Probes and Primers

In another aspect, the invention provides a polynucleotide (either DNA or RNA) that comprises at least about 20 nt, still more preferably at least about 30 nt, and even more preferably at least about 30-1950 nt of a nucleic acid molecule described herein. These are useful as diagnostic probes and primers as discussed above and in more detail below.

-20-

By a portion of a polynucleotide of "at least 10 nt in length," for example, is intended 10 or more contiguous nucleotides from the nucleotide sequence of the reference polynucleotide (e.g., at least one deposited nucleic acid or
5 at least one nucleotide sequence as shown in at least one of SEQ ID NO:1 and SEQ ID NO:2).

Of course, a polynucleotide which hybridizes only to a poly A sequence (such as the 3' terminal poly(A) of a hOB-BP2h cDNA shown in at least one of SEQ ID NO:1, SEQ ID NO:2,
10 or to a complementary stretch of T (or U) residues, would not be included in a probe of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

15 The present invention also provides subsequences of full-length nucleic acids. Any number of subsequences can be obtained by reference to at least one of SEQ ID NO:1, SEQ ID NO:2, or a complementary sequence, and using primers which selectively amplify, under stringent conditions to: at least
20 two sites to the polynucleotides of the present invention, or to two sites within the nucleic acid which flank and comprise a polynucleotide of the present invention, or to a site within a polynucleotide of the present invention and a site within the nucleic acid which comprises it. A variety of
25 methods for obtaining 5' and 3' ends is well known in the art. See, e.g., RACE (Rapid Amplification of Complementary Ends) as described in M. A. Frohman, PCR Protocols: A Guide to Methods and Applications, M. A. Innis, et al, Eds., Academic Press, Inc., San Diego, CA, pp. 28-38 (1990); see
30 also, U.S. Patent No. 5,470,722, and Ausubel, et al., Current Protocols in Molecular Biology, Chapter 15, Eds., John Wiley & Sons, N.Y. (1989-1999). Thus, the present invention provides hOB-BP2h polynucleotides having the sequence of the

-21-

hOB-BP2h gene, nuclear transcript, cDNA, or complementary sequences and subsequences thereof.

Primer sequences can be obtained by reference to a contiguous subsequence of a polynucleotide of the present invention. Primers are chosen to selectively hybridize, under PCR amplification conditions, to a polynucleotide of the present invention in an amplification mixture comprising a genomic and cDNA library from the same species. Generally, the primers are complementary to a subsequence of the amplified nucleic acid. In some embodiments, the primers will be constructed to anneal at their 5' terminal ends to the codon encoding the carboxy or amino terminal amino acid residue (or the complements thereof) of the polynucleotides of the present invention. The primer length in nucleotides is selected from the group of integers consisting of from at least 15 to 50. Thus, the primers can be at least 15, 18, 20, 25, 30, 40, or 50 nucleotides in length or any range or value therein. A non-annealing sequence at the 5' end of the primer (a "tail") can be added, for example, to introduce a cloning site at the terminal ends of the amplified DNA.

The amplification primers may optionally be elongated in the 3' direction with additional contiguous or complementary nucleotides from the polynucleotide sequences, such as at least one of SEQ ID NO:1 and SEQ ID NO:2, from which they are derived. The number of nucleotides by which the primers can be elongated is selected from the group of integers consisting of from at least 1 to at least 25. Thus, for example, the primers can be elongated with an additional 1, 5, 10, or 15 nucleotides or any range or value therein. Those of skill will recognize that a lengthened primer sequence can be employed to increase specificity of binding (i.e., annealing) to a target sequence, or to add useful sequences, such as links or restriction sites (See e.g., Ausubel, *supra*, Chapter 15).

-22-

The amplification products can be translated using expression systems well known to those of skill in the art and as discussed, *infra*. The resulting translation products can be confirmed as polypeptides of the present invention by, for example, assaying for the appropriate catalytic activity (e.g., specific activity and substrate specificity), or verifying the presence of one or more linear epitopes which are specific to a polypeptide of the present invention. Methods for protein synthesis from PCR derived templates are known in the art (See e.g., Ausubel, *supra*, Chapters 9, 10, 15; Coligan, *Current Protocols in Protein Science, supra*, Chapter 5) and available commercially. See, e.g., Amersham Life Sciences, Inc., Catalog '97, p. 354.

Polynucleotides Which Selectively Hybridize to a Polynucleotide as Described Herein

The present invention provides isolated nucleic acids that hybridize under selective hybridization conditions to a polynucleotide disclosed herein, e.g., SEQ ID NO:1 and SEQ ID NO:2. Thus, the polynucleotides of this embodiment can be used for isolating, detecting, and quantifying nucleic acids comprising such polynucleotides. For example, polynucleotides of the present invention can be used to identify, isolate, or amplify partial or full-length clones in a deposited library. In some embodiments, the polynucleotides are genomic or cDNA sequences isolated, or otherwise complementary to, a cDNA from a human or mammalian nucleic acid library.

Preferably, the cDNA library comprises at least 80% full-length sequences, preferably at least 85% or 90% full-length sequences, and more preferably at least 95% full-length sequences. The cDNA libraries can be normalized to increase the representation of rare sequences. Low

-23-

stringency hybridization conditions are typically, but not exclusively, employed with sequences having a reduced sequence identity relative to complementary sequences. Moderate and high stringency conditions can optionally be employed for sequences of greater identity. Low stringency conditions allow selective hybridization of sequences having about 70% sequence identity and can be employed to identify orthologous or paralogous sequences.

Optionally, polynucleotides of this invention will encode an epitope of a polypeptide encoded by the polynucleotides described herein. The polynucleotides of this invention embrace nucleic acid sequences that can be employed for selective hybridization to a polynucleotide encoding a polypeptide of the present invention.

Screening polypeptides for specific binding to antibodies or fragments can be conveniently achieved using peptide display libraries. This method involves the screening of large collections of peptides for individual members having the desired function or structure. Antibody screening of peptide display libraries is well known in the art. The displayed peptide sequences can be from 3 to 5000 or more amino acids in length, frequently from 5-100 amino acids long, and often from about 8 to 15 amino acids long. In addition to direct chemical synthetic methods for generating peptide libraries, several recombinant DNA methods have been described. One type involves the display of a peptide sequence on the surface of a bacteriophage or cell. Each bacteriophage or cell contains the nucleotide sequence encoding the particular displayed peptide sequence. Such methods are described in PCT Patent Publication Nos. 91/17271, 91/18980, 91/19818, and 93/08278. Other systems for generating libraries of peptides have aspects of both in vitro chemical synthesis and recombinant methods. See, PCT Patent Publication Nos. 92/05258, 92/14843, and 96/19256.

-24-

See also, U.S. Patent Nos. 5,658,754; and 5,643,768. Peptide display libraries, vector, and screening kits are commercially available from such suppliers as Invitrogen (Carlsbad, CA).

5

Polynucleotides Complementary to the Polynucleotides

As indicated above, the present invention provides isolated nucleic acids comprising hOB-BP2h polynucleotides, wherein the polynucleotides are complementary to the
10 polynucleotides described herein, above. As those of skill in the art will recognize, complementary sequences base pair throughout the entirety of their length with such polynucleotides (i.e., have 100% sequence identity over their entire length). Complementary bases associate through
15 hydrogen bonding in double-stranded nucleic acids. For example, the following base pairs are complementary: guanine and cytosine; adenine and thymine; and adenine and uracil. (See, e.g., Ausubel, *supra*, Chapter 67; or Sambrook, *supra*)

Construction of Nucleic Acids

The isolated nucleic acids of the present invention can be made using (a) standard recombinant methods, (b) synthetic techniques, (c) purification techniques, or combinations thereof, as well known in the art.

25 The nucleic acids may conveniently comprise sequences in addition to a polynucleotide of the present invention. For example, a multi-cloning site comprising one or more endonuclease restriction sites may be inserted into the nucleic acid to aid in isolation of the polynucleotide.
30 Also, translatable sequences may be inserted to aid in the isolation of the translated polynucleotide of the present invention. For example, a hexa-histidine marker sequence provides a convenient means to purify the proteins of the

- 25 -

present invention. The nucleic acid of the present invention - excluding the polynucleotide sequence - is optionally a vector, adapter, or linker for cloning and expression of a polynucleotide of the present invention.

5 Additional sequences may be added to such cloning and
expression sequences to optimize their function in cloning
and expression, to aid in isolation of the polynucleotide, or
to improve the introduction of the polynucleotide into a
cell. Typically, the length of a nucleic acid of the present
10 invention less the length of its polynucleotide of the
present invention is less than 20 kilobase pairs, often less
than 15 kb, and frequently less than 10 kb. Use of cloning
vectors, expression vectors, adapters, and linkers is well
known in the art. (See, e.g., Ausubel, *supra*, Chapters 1-5;
15 or Sambrook, *supra*).

Recombinant Methods for Constructing Nucleic Acids

The isolated nucleic acid compositions of this invention, such as RNA, cDNA, genomic DNA, or a hybrid thereof, can be obtained from biological sources using any number of cloning methodologies known to those of skill in the art. In some embodiments, oligonucleotide probes that selectively hybridize, under stringent conditions, to the polynucleotides of the present invention are used to identify the desired sequence in a cDNA or genomic DNA library. While isolation of RNA, and construction of cDNA and genomic libraries is well known to those of ordinary skill in the art. (See, e.g., Ausubel, *supra*, Chapters 1-7; or Sambrook, *supra*)

Nucleic Acid Screening and Isolation Methods

A cDNA or genomic library can be screened using a probe based upon the sequence of a polynucleotide of the present

-26-

invention, such as those disclosed herein. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate homologous genes in the same or different organisms. Those of skill in the art will appreciate that various
5 degrees of stringency of hybridization can be employed in the assay; and either the hybridization or the wash medium can be stringent. As the conditions for hybridization become more stringent, there must be a greater degree of complementarity between the probe and the target for duplex formation to
10 occur. Temperature, ionic strength, pH and the presence of a partially denaturing solvent such as formamide can control the degree of stringency. Changing the polarity of the reactant solution through, for example, manipulation of the concentration of formamide within the range of 0% to 50%
15 conveniently varies the stringency of hybridization. The degree of complementarity (sequence identity) required for detectable binding will vary in accordance with the stringency of the hybridization medium and wash medium. The degree of complementarity will optimally be 100%; however, it
20 should be understood that minor sequence variations in the probes and primers may be compensated for by reducing the stringency of the hybridization and wash medium.

Methods of amplification of RNA or DNA are well known in the art and can be used according to the present
25 invention without undue experimentation, based on the teaching and guidance presented herein.

Known methods of DNA or RNA amplification include, but are not limited to, polymerase chain reaction (PCR) and related amplification processes (see, e.g., U.S. Patent Nos.
30 4,683,195, 4,683,202, 4,800,159, 4,965,188, to Mullis, et al.; 4,795,699 and 4,921,794 to Tabor, et al; 5,142,033 to Innis; 5,122,464 to Wilson, et al.; 5,091,310 to Innis; 5,066,584 to Gyllensten, et al; 4,889,818 to Gelfand, et al; 4,994,370 to Silver, et al; 4,766,067 to Biswas; 4,656,134

-27-

to Ringold) and RNA mediated amplification which uses anti-sense RNA to the target sequence as a template for double-stranded DNA synthesis (U.S. Patent No. 5,130,238 to Malek, et al, with the tradename NASBA), the entire contents of which are herein incorporated by reference. (See, e.g., Ausubel, *supra*, Chapter 15; or Sambrook, *supra*)

For instance, polymerase chain reaction (PCR) technology can be used to amplify the sequences of polynucleotides of the present invention and related genes directly from genomic DNA or cDNA libraries. PCR and other in vitro amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes. Examples of techniques sufficient to direct persons of skill through in vitro amplification methods are found in Berger, Sambrook, and Ausubel (e.g., Chapter 15) *supra*, as well as Mullis, et al., U.S. Patent No. 4,683,202 (1987); and Innis, et al., PCR Protocols A Guide to Methods and Applications, Eds., Academic Press Inc., San Diego, CA (1990). Commercially available kits for genomic PCR amplification are known in the art. See, e.g., Advantage-GC Genomic PCR Kit (Clontech). The T4 gene 32 protein (Boehringer Mannheim) can be used to improve yield of long PCR products.

Synthetic Methods for Constructing Nucleic Acids

The isolated nucleic acids of the present invention can also be prepared by direct chemical synthesis by methods such as the phosphotriester method of Narang, et al., Meth. Enzymol. 68:90-99 (1979); the phosphodiester method of Brown, et al., Meth. Enzymol. 68:109-151 (1979); the diethylphosphoramidite method of Beaucage, et al., Tetra.

-28-

Letts. 22:1859-1862 (1981); the solid phase phosphoramidite triester method described by Beaucage and Caruthers, Tetra. Letts. 22(20):1859-1862 (1981), e.g., using an automated synthesizer, e.g., as described in Needham-VanDevanter, et al., Nucleic Acids Res. 12:6159-6168 (1984); and the solid support method of U.S. Patent No. 4,458,066. Chemical synthesis generally produces a single-stranded oligonucleotide, which may be converted into double-stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template. One of skill in the art will recognize that while chemical synthesis of DNA can be limited to sequences of about 100 or more bases, longer sequences may be obtained by the ligation of shorter sequences.

Recombinant Expression Cassettes

The present invention further provides recombinant expression cassettes comprising a nucleic acid of the present invention. A nucleic acid sequence of the present invention, for example a cDNA or a genomic sequence encoding a full-length polypeptide of the present invention, can be used to construct a recombinant expression cassette which can be introduced into at least one desired host cell. A recombinant expression cassette will typically comprise a polynucleotide of the present invention operably linked to transcriptional initiation regulatory sequences that will direct the transcription of the polynucleotide in the intended host cell.

Both heterologous and non-heterologous (i.e., endogenous) promoters can be employed to direct expression of the nucleic acids of the present invention. These promoters can also be used, for example, in recombinant expression cassettes to drive expression of antisense nucleic acids to

-29-

reduce, increase, or alter hOB-BP2h content and composition in a desired tissue.

In some embodiments, isolated nucleic acids which serve as promoter or enhancer elements can be introduced in the appropriate position (generally upstream) of a non-heterologous form of a polynucleotide of the present invention so as to up or down regulate expression of a polynucleotide of the present invention. For example, endogenous promoters can be altered *in vivo* or *in vitro* by mutation, deletion and substitution.

A polynucleotide of the present invention can be expressed in either sense or anti-sense orientation as desired. It will be appreciated that control of gene expression in either sense or anti-sense orientation can have a direct impact on the observable characteristics.

Another method of suppression is sense suppression. Introduction of nucleic acid configured in the sense orientation has been shown to be an effective means by which to block the transcription of target genes.

A variety of cross-linking agents, alkylating agents and radical generating species as pendant groups on polynucleotides of the present invention can be used to bind, label, detect and cleave nucleic acids. Knorre, et al., *Biochimie* 67:785-789 (1985); Vlassov, et al., *Nucleic Acids Res.* 14:4065-4076 (1986); Iverson and Dervan, *J. Am. Chem. Soc.* 109:1241-1243 (1987); Meyer, et al., *J. Am. Chem. Soc.* 111:8517-8519 (1989); Lee, et al., *Biochemistry* 27:3197-3203 (1988); Home, et al., *J. Am. Chem. Soc.* 112:2435-2437 (1990); Webb and Matteucci, *J. Am. Chem. Soc.* 108:2764-2765 (1986); Nucleic Acids Res. 14:7661-7674 (1986); Feteritz, et al., *J. Am. Chem. Soc.* 113:4000 (1991). Various compounds to bind, detect, label, and cleave nucleic acids are known in the art. See, for example, U.S. Patent Nos. 5,543,507; 5,672,593;

-30-

5,484,908; 5,256,648; and 5,681,941, each entirely incorporated herein by reference.

VECTORS AND HOST CELLS

5 The present invention also relates to vectors that include isolated nucleic acid molecules of the present invention, host cells that are genetically engineered with the recombinant vectors, and the production of hOB-BP2h polypeptides or fragments thereof by recombinant techniques,
10 as is well known in the art. See, e.g., Sambrook, et al., *supra*; Ausubel, *supra*, Chapters 1-9, each entirely incorporated herein by reference.

 The polynucleotides can optionally be joined to a vector containing a selectable marker for propagation in a
15 host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it can be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

20 The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli lac*, *trp* and *tac* promoters, the SV40 early and late promoters and promoters of retroviral LTRs, or any other suitable promoter. The skilled artisan will know
25 other suitable promoters. The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome-binding site for translation. The coding portion of the mature transcripts expressed by the constructs will
30 preferably include a translation initiating at the beginning and a termination codon (e.g., UAA, UGA or UAG) appropriately positioned at the end of the mRNA to be

-31-

translated, with VAA and VAG preferred for mammalian or eukaryotic cell expression.

Expression vectors will preferably include at least one selectable marker. Such markers include, e.g.,

5 dihydrofolate reductase, ampicillin (G418), hygromycin or neomycin resistance for eukaryotic cell culture, and tetracycline or ampicillin resistance genes for culturing in *E. coli* and other bacteria or prokaryotics. Representative examples of appropriate hosts include, but are not limited

10 to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS and Bowes melanoma cells; and plant cells. Appropriate culture mediums and

15 conditions for the above-described host cells are known in the art. Vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available from Stratagene; and ptrc99a,

20 pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia.

Preferred eucaryotic vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled

25 artisan. See, e.g., Ausubel, *supra*, Chapter 1; Coligan, Current Protocols in Protein Science, *supra*, Chapter 5.

Introduction of a vector construct into a host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection,

30 electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals, such as Sambrook, *supra*, Chapters 1-4 and 16-18; Ausubel, *supra*, Chapters 1, 9, 13, 15, 16.

-32-

Polypeptide(s) of the present invention can be expressed in a modified form, such as a fusion protein, and can include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino acids, particularly charged amino acids, can be added to the N-terminus of a polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties can be added to a polypeptide to facilitate purification. Such regions can be removed prior to final preparation of a polypeptide. Such methods are described in many standard laboratory manuals, such as Sambrook, *supra*, Chapters 17 and 18; Ausubel, *supra*, Chapters 16, 17 and 18.

Expression of Proteins in Host Cells

Using nucleic acids of the present invention, one may express a protein of the present invention in a recombinantly engineered cell, such as bacteria, yeast, insect, or mammalian cells. The cells produce the protein in a non-natural condition (e.g., in quantity, composition, location, and time), because they have been genetically altered through human intervention to do so.

It is expected that those of skill in the art are knowledgeable in the numerous expression systems available for expression of a nucleic acid encoding a protein of the present invention. No attempt to describe in detail the various methods known for the expression of proteins in prokaryotes or eukaryotes will be made.

In brief summary, the expression of isolated nucleic acids encoding a protein of the present invention will typically be achieved by operably linking, for example, the DNA or cDNA to a promoter (which is either constitutive or

-33-

inducible) followed by incorporation into an expression vector. The vectors can be suitable for replication and integration in either prokaryotes or eukaryotes. Typical expression vectors contain transcription and translation terminators, initiation sequences and promoters useful for regulation of the expression of the DNA encoding a protein of the present invention. To obtain high level expression of a cloned gene, it is desirable to construct expression vectors which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator. One of skill would recognize that modifications can be made to a protein of the present invention without diminishing its biological activity. Some modifications may be made to facilitate the cloning, expression, or incorporation of the targeting molecule into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (e.g., poly His) placed on either terminus to create conveniently located restriction sites or termination codons or purification sequences.

Alternatively, nucleic acids of the present invention can be expressed in a host cell by turning on (by manipulation) in a host cell that contains endogenous DNA encoding a polypeptide of the present invention. Such methods are well known in the art, e.g., as described in US patent Nos. 5,580,734, 5,641,670, 5,733,746, and 5,733,761, entirely incorporated herein by reference.

Expression in Prokaryotes

Prokaryotic cells may be used as hosts for expression. Prokaryotes most frequently are represented by various

-34-

strains of *E. coli*; however, other microbial strains may also be used. Commonly used prokaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta lactamase (penicillinase) and lactose (*lac*) promoter systems (Chang, et al., *Nature* 198:1056 (1977)), the tryptophan (*trp*) promoter system (Goeddel, et al., *Nucleic Acids Res.* 8:4057 (1980)) and the lambda derived P_L promoter and N-gene ribosome binding site (Shimatake, et al., *Nature* 292:128 (1981)). The inclusion of selection markers in DNA vectors transfected in *E. coli* is also useful. Examples of such markers include genes specifying resistance to ampicillin, tetracycline, or chloramphenicol.

The vector is selected to allow introduction into the appropriate host cell. Bacterial vectors are typically of plasmid or phage origin. Appropriate bacterial cells are infected with phage vector particles or transfected with naked phage vector DNA. If a plasmid vector is used, the bacterial cells are transformed with the plasmid vector DNA. Expression systems for expressing a protein of the present invention are available using *Bacillus* sp. and *Salmonella* (Palva, et al., *Gene* 22:229-235 (1983); Mosbach, et al., *Nature* 302:543-545 (1983)). See, e.g., Ausubel, *supra*, Chapters 1-3, 16(Sec.1); and Coligan, *supra*, Current Protocols in Protein Science, Units 5.1, 6.1-6.7.

Expression in Eukaryotes

A variety of eukaryotic expression systems such as yeast, insect cell lines, plant and mammalian cells, are known to those of skill in the art. As explained briefly below, a nucleic acid of the present invention can be expressed in these eukaryotic systems.

-35-

Synthesis of heterologous proteins in yeast is well known. F. Sherman, et al., Methods in Yeast Genetics, Cold Spring Harbor Laboratory (1982) is a well-recognized work describing the various methods available to produce the protein in yeast. Two widely utilized yeast for production of eukaryotic proteins are *Saccharomyces cerevisiae* and *Pichia pastoris*. Vectors, strains, and protocols for expression in *Saccharomyces* and *Pichia* are known in the art and available from commercial suppliers (e.g., Invitrogen). Suitable vectors usually have expression control sequences, such as promoters, including 3-phosphoglycerate kinase or alcohol oxidase, and an origin of replication, termination sequences and the like as desired.

A protein of the present invention, once expressed, can be isolated from yeast by lysing the cells and applying standard protein isolation techniques to the lysates. The monitoring of the purification process can be accomplished by using Western blot techniques or radioimmunoassay of other standard immunoassay techniques.

The sequences encoding proteins of the present invention can also be ligated to various expression vectors for use in transfecting cell cultures of, for instance, mammalian, insect, or plant origin. Illustrative of cell cultures useful for the production of the peptides are mammalian cells. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may also be used. A number of suitable host cell lines capable of expressing intact proteins have been developed in the art, and include the HEK293, BHK21, and CHO cell lines.

Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter (e.g., the CMV promoter, a HSV tk promoter or pgk (phosphoglycerate kinase) promoter), an enhancer (Queen, et al., Immunol. Rev. 89:49 (1986)), and processing information

-36-

sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites (e.g., an SV40 large T Ag poly A addition site), and transcriptional terminator sequences. Other animal cells useful for production of proteins of the present invention are available, for instance, from the American Type Culture Collection Catalogue of Cell Lines and Hybridomas (7th edition, 1992).

Appropriate vectors for expressing proteins of the present invention in insect cells are usually derived from the SF9 baculovirus. Suitable insect cell lines include mosquito larvae, silkworm, armyworm, moth and *Drosophila* cell lines such as a Schneider cell line (See Schneider, J. Embryol. Exp. Morphol. 27:353-365 (1987)).

As with yeast, when higher animal or plant host cells are employed, polyadenylation or transcription terminator sequences are typically incorporated into the vector. An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript may also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague, et al., J. Virol. 45:773-781 (1983)). Additionally, gene sequences to control replication in the host cell may be incorporated into the vector such as those found in bovine papilloma virus type-vectors. M. Saveria-Campo, Bovine Papilloma Virus DNA, a Eukaryotic Cloning Vector in DNA Cloning Vol. II, a Practical Approach, D. M. Glover, Ed., IRL Press, Arlington, VA, pp. 213-238 (1985).

Protein Purification

A hOB-BP2h polypeptide can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography,

-37-

phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed
5 for purification. Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eucaryotic host, including, for example, bacterial, yeast, higher plant, insect and
10 mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention can be glycosylated or can be non-glycosylated. In addition, polypeptides of the invention can also include an initial modified methionine residue, in
15 some cases as a result of host-mediated processes. Such methods are described in many standard laboratory manuals, such as Sambrook, supra, Chapters 17.37-17.42; Ausubel, supra, Chapters 10, 12, 13, 16, 18 and 20.

hOB-BP2h POLYPEPTIDES AND FRAGMENTS AND VARIANTS

20 The invention further provides isolated hOB-BP2h polypeptides having fragments or specified variants of the amino acid sequence encoded by the deposited cDNAs, or the amino acid sequences in SEQ ID NO:3, 4, or 5.

The isolated proteins of the present invention comprise
25 a polypeptide encoded by any one of the polynucleotides of the present invention as discussed more fully, supra, or polypeptides which are specified fragments or variants thereof.

Exemplary polypeptide sequences are provided in SEQ ID
30 NO:3, 4, or 5. The proteins of the present invention, or variants thereof, can comprise any number of contiguous amino acid residues from a polypeptide of the present invention, wherein that number is selected from the group of integers

-38-

consisting of from 90-100% of the number of contiguous residues in a full-length hOB-BP2h polypeptide. Optionally, this subsequence of contiguous amino acids is at least 50, 60, 70, 80, or 90 amino acids in length. Further, the number
5 of such subsequences can be any integer selected from the group consisting of from 1 to 20, such as 2, 3, 4, or 5.

As those of skill will appreciate, the present invention includes biologically active polypeptides of the present invention (i.e., enzymes). Biologically active polypeptides
10 have a specific activity at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%, and most preferably at least 80%, 90%, or 95%-1000% of that of the native (non-synthetic), endogenous polypeptide. Further, the substrate specificity (e.g., k_{cat}/K_m) is optionally substantially
15 similar to the native (non-synthetic), endogenous polypeptide. Typically, the K_m will be at least 30%, 40%, or 50%, that of the native (non-synthetic), endogenous polypeptide; and more preferably at least 60%, 70%, 80%, or 90%-1000%. Methods of assaying and quantifying measures of
20 enzymatic activity and substrate specificity, are well known to those of skill in the art.

Generally, the polypeptides of the present invention will, when presented as an immunogen, elicit production of an antibody specifically reactive to a polypeptide of the
25 present invention encoded by a polynucleotide of the present invention as described, supra. Exemplary polypeptides include those which are full-length, such as those disclosed herein. Further, the proteins of the present invention will not bind to antisera raised against a polypeptide of the
30 present invention which has been fully immunosorbed with the same polypeptide. Immunoassays for determining binding are well known to those of skill in the art. A preferred immunoassay is a competitive immunoassay as discussed, infra. Thus, the proteins of the present invention can be employed

-39-

as immunogens for constructing antibodies immunoreactive to a protein of the present invention for such exemplary utilities as immunoassays or protein purification techniques.

A hOB-BP2h polypeptide of the present invention can
5 include one or more amino acid substitutions, deletions or additions, either from natural mutations or human manipulation, as specified herein.

Of course, the number of amino acid substitutions a skilled artisan would make depends on many factors,
10 including those described above. Generally speaking, the number of amino acid substitutions, insertions or deletions for any given hOB-BP2h polypeptide will not be more than 40, 30, 20, 10, 5, or 3, such as 1-30 or any range or value therein, as specified herein.

15 Amino acids in a hOB-BP2h polypeptide of the present invention that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, Science 244:1081-1085 (1989)). The latter procedure
20 introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity. Sites that are critical for ligand-protein binding can also be identified by structural analysis such as crystallization, nuclear magnetic resonance
25 or photoaffinity labeling (Smith, et al., J. Mol. Biol. 224:899-904 (1992) and de Vos, et al., Science 255:306-312 (1992)).

hOB-BP2h polypeptides of the present invention can include but are not limited to, at least one selected from
30 the extracellular domain, intracellular domain, transmembrane domain, and active domain of SEQ ID NO:3, 4, or 5.

-40-

A hOB-BP2h polypeptide can further comprise a polypeptide of at least one of 512 or 639 contiguous amino acids of SEQ ID NO:3 or SEQ ID NO:4, respectively.

A hOB-BP2h polypeptide further includes an amino acid sequence selected from one or more of SEQ ID NO:3, 4, or 5.

Non-limiting mutants that can enhance or maintain at least one of the listed activities include, but are not limited to, any of the above polypeptides, further comprising at least one mutation corresponding to at least one substitution, insertion or deletion selected from the group consisting of 3P, 4L, 8P, 9L, 11W, 15L, 16Q, 17E, 18K, 19P, 20V, 21Y, 22E, 23L, 24Q, 27K, 30T, 32Q, 37V, 38L, 47W, 48R, 49S, 51Y, 52S, 54P, 56L, 58V, 70A, 71E, 72V, 77N, 78P, 79D, 81R, 83K, 84P, 85E, 87Q, 91R, 93L, 96V, 97Q, 99K, 104S, 106G, 109R, 111E, 113T, 114G, 115S, 124R, 125D, 127K, 129S, 130Y, 131Q, 132Q, 133N, 134K, 135L, 136N, 138E, 141V, 143S, 143I, 144F, 144E, 145T, 210N, and 252A of SEQ ID NO:3, or 3P, 4L, 8P, 9L, 11W, 15L, 16Q, 17E, 18K, 19P, 20V, 21Y, 22E, 23L, 24Q, 27K, 30T, 32Q, 37V, 38L, 47W, 48R, 49S, 51Y, 52S, 54P, 56L, 58V, 70A, 71E, 72V, 77N, 78P, 79D, 81R, 83K, 84P, 85E, 87Q, 91R, 93L, 96V, 97Q, 99K, 104S, 106G, 109R, 111E, 113T, 114G, 115S, 124R, 125D, 127K, 129S, 130Y, 131Q, 132Q, 133N, 134K, 135L, 136N, 138E, 141A, 143T, 143I, 144Q, 144E, 145K, 152D, 194D, 386S, 387L, 389Q, 405R, 408F, 409R, 411R, 417C, 419R, 421E, 423K, 424P, 432G, 435K, 437N, 438G, 450I, 458D, 460K, 461V, 462S, 464K, 468I, 469Y, 471S, and 476V of SEQ ID NO:4.

Antigenic/Epitope Comprising hOB-BP2h Peptide and

Polypeptides

In another aspect, the invention provides a peptide or polypeptide comprising an epitope-bearing portion of a polypeptide of the invention according to methods well known

-41-

in the art. See, e.g., Colligan, et al., ed., Current Protocols in Immunology, Greene Publishing, NY (1993-1998), Ausubel, *supra*, each entirely incorporated herein by reference.

5 The epitope of this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide described herein. An "immunogenic epitope" can be defined as a part of a polypeptide that elicits an antibody response when the whole polypeptide is the immunogen. On the other hand, a
10 region of a polypeptide molecule to which an antibody can bind is defined as an "antigenic epitope." The number of immunogenic epitopes of a polypeptide generally is less than the number of antigenic epitopes. See, for instance, Geysen, et al., Proc. Natl. Acad. Sci. USA 81:3998-4002
15 (1983).

As to the selection of peptides or polypeptides bearing an antigenic epitope (i.e., that contain at least a portion of a region of a polypeptide molecule to which an antibody can bind), it is well known in the art that relatively short
20 synthetic peptides that mimic part of a polypeptide sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked polypeptide. See, for instance, J. G. Sutcliffe, et al., "Antibodies that react with preidentified sites on polypeptides," Science 219:660-666
25 (1983).

Antigenic epitope-bearing peptides and polypeptides of the invention are useful to raise antibodies, including monoclonal antibodies, or screen antibodies, including fragments or single chain antibodies, that bind specifically
30 to a polypeptide of the invention. See, for instance, Wilson, et al., Cell 37:767-778 (1984) at 777. Antigenic epitope-bearing peptides and polypeptides of the invention preferably contain a sequence of at least five, more preferably at least nine, and most preferably between at

-42-

least about 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention.

The epitope-bearing peptides and polypeptides of the invention can be produced by any conventional means. R. A. Houghten, "General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids," Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985). This "Simultaneous Multiple Peptide Synthesis (SMPS)" process is further described in U.S. Patent No. 4,631,211 to Houghten, et al. (1986).

As one of skill in the art will appreciate, hOB-BP2h polypeptides of the present invention and the epitope-bearing fragments thereof described above can be combined with parts of the constant domain of immunoglobulins (Fc), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. This has been shown, e.g., for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins (EPA 394,827; Traunecker, et al., Nature 331:84-86 (1988)). Fusion proteins that have a disulfide-linked dimeric structure due to the IgG part can also be more efficient in binding and neutralizing other molecules than the monomeric hOB-BP2h polypeptide or polypeptide fragment alone (Fountoulakis, et al., J. Biochem. 270:3958-3964 (1995)).

Production of Antibodies

The polypeptides of this invention and fragments thereof may be used in the production of antibodies. The term "antibody" as used herein describes antibodies, fragments of antibodies (such as, but not limited, to Fab,

-43-

Fab', Fab2', and Fv fragments), and modified versions thereof, as well known in the art (e.g., chimeric, humanized, recombinant, veneered, resurfaced or CDR-grafted) such antibodies are capable of binding antigens of a similar nature as the parent antibody molecule from which they are derived. The instant invention also encompasses single chain polypeptide binding molecules.

The production of antibodies, both monoclonal and polyclonal, in animals is well known in the art. See, e.g., Colligan, supra, entirely incorporated herein by reference.

Single chain antibodies and libraries thereof are yet another variety of genetically engineered antibody technology that is well known in the art. (See, e.g., R. E. Bird, et al., Science 242:423-426 (1988); PCT Publication Nos. WO 88/01649, WO 90/14430, and WO 91/10737. Single chain antibody technology involves covalently joining the binding regions of heavy and light chains to generate a single polypeptide chain. The binding specificity of the intact antibody molecule is thereby reproduced on a single polypeptide chain.

Antibodies included in this invention are useful in diagnostics, therapeutics or in diagnostic/therapeutic combinations.

The polypeptides of this invention or suitable fragments thereof can be used to generate polyclonal or monoclonal antibodies, and various inter-species hybrids, or humanized antibodies, or antibody fragments, or single-chain antibodies. The techniques for producing antibodies are well known to skilled artisans. (See, e.g., Colligan supra; Monoclonal Antibodies: Principles & Applications, Ed. J. R. Birch & E. S. Lennox, Wiley-Liss (1995).

A polypeptide used as an immunogen may be modified or administered in an adjuvant, by subcutaneous or intraperitoneal injection into, for example, a mouse or a

-44-

rabbit. For the production of monoclonal antibodies, spleen cells from immunized animals are removed, fused with myeloma or other suitable known cells, and allowed to become monoclonal antibody producing hybridoma cells in the manner known to the skilled artisan. Hybridomas that secrete a desired antibody molecule can be screened by a variety of well known methods, for example ELISA assay, Western blot analysis, or radioimmunoassay (Lutz, et al. Exp. Cell Res. 175:109-124 (1988); Monoclonal Antibodies: Principles & Applications, Ed. J. R. Birch & E. S. Lennox, Wiley-Liss (1995); Colligan, supra).

For some applications labeled antibodies are desirable. Procedures for labeling antibody molecules are widely known, including for example, the use of radioisotopes, affinity labels, such as biotin or avidin, enzymatic labels, for example horseradish peroxidase, and fluorescent labels, such as FITC or rhodamine (See, e.g., Colligan, supra).

Labeled antibodies are useful for a variety of diagnostic applications. In one embodiment the present invention relates to the use of labeled antibodies to detect the presence of a hOB-BP2h polypeptide. Alternatively, the antibodies could be used in a screen to identify potential modulators of a hOB-BP2h polypeptide. For example, in a competitive displacement assay, the antibody or compound to be tested is labeled by any suitable method. Competitive displacement of an antibody from an antibody-antigen complex by a test compound such that a test compound-antigen complex is formed provides a method for identifying compounds that bind HPLFP.

30

Transgenics and Chimeric Non-Human Mammals

The present invention is also directed to a transgenic non-human eukaryotic animal (preferably a rodent, such as a

-45-

mouse) the germ cells and somatic cells of which contain nucleic acid genomic DNA according to the present invention which codes for at least one hOB-BP2h polypeptide. At least one hOB-BP2h nucleic acid can be introduced into the animal
5 to be made transgenic, or an ancestor of the animal, at an embryonic stage, preferably the 1-1000 cell or oocyte, stage, and preferably not later than about the 64-cell stage. The term "transgene," as used herein, means a gene which is incorporated into the genome of the animal and is expressed
10 in the animal, resulting in the presence of at least one hOB-BP2h polypeptide in the transgenic animal.

There are several means by which such a hOB-BP2h nucleic acid can be introduced into a cell or genome of the animal embryo so as to be chromosomally incorporated and expressed
15 according to known methods.

Chimeric non-human mammals in which fewer than all of the somatic and germ cells contain the a hOB-BP2h polypeptide nucleic acid of the present invention, such as animals produced when fewer than all of the cells of the morula are
20 transfected in the process of producing the transgenic animal, are also intended to be within the scope of the present invention.

Chimeric non-human mammals having human cells or tissue engrafted therein are also encompassed by the present
25 invention, which may be used for testing expression of at least one hOB-BP2h polypeptide in human tissue and for testing the effectiveness of therapeutic and diagnostic agents associated with delivery vectors which preferentially bind to a hOB-BP2h polypeptide of the present invention.
30 Methods for providing chimeric non-human mammals are provided, e.g., in U.S. Serial Nos. 07/508,225, 07/518,748, 07/529,217, 07/562,746, 07/596,518, 07/574,748, 07/575,962, 07/207,273, 07/241,590 and 07/137,173, which are entirely

-46-

incorporated herein by reference, for their description of how to engraft human cells or tissue into non-human mammals.

The techniques described in Leder, U.S. Patent No. 4,736,866 (hereby entirely incorporated by reference) for
5 producing transgenic non-human mammals may be used for the production of a transgenic non-human mammal of the present invention. The various techniques described in U.S. patent Nos. 5,454,807, 5,073,490, 5,347,075 and 4,736,866, the entire contents of which are hereby incorporated by
10 reference, may also be used.

Animals carrying at least one hOB-BP2h polypeptide and nucleic acid can be used to test compounds or other treatment modalities which may prevent, suppress or cure a pathology relating to at least one hOB-BP2h polypeptide or hOB-BP2h
15 nucleic acid. Such transgenic animals will also serve as a model for testing of diagnostic methods for the same diseases. Transgenic animals according to the present invention can also be used as a source of cells for cell culture.

20 Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

25 **Example 1: Expression and Purification of an hOB-BP2h Polypeptide in E. coli**

The bacterial expression vector pQE60 is used for bacterial expression in this example. (QIAGEN, Inc., Chatsworth, CA). pQE60 encodes ampicillin antibiotic
30 resistance ("Ampr") and contains a bacterial origin of replication ("ori"), an IPTG inducible promoter, a ribosome binding site ("RBS"), six codons encoding histidine residues that allow affinity purification using nickel-nitrilo-tri-

-47-

acetic acid ("Ni-NTA") affinity resin sold by QIAGEN, Inc., and suitable single restriction enzyme cleavage sites. These elements are arranged such that a DNA fragment encoding a polypeptide can be inserted in such a way as to produce that polypeptide with the six His residues (i.e., a "6 X His tag") covalently linked to the carboxyl terminus of that polypeptide. However, a polypeptide coding sequence can optionally be inserted such that translation of the six His codons is prevented and, therefore, a polypeptide is produced with no 6 X His tag.

The nucleic acid sequence encoding the desired portion of a hOB-BP2h polypeptide lacking the hydrophobic leader sequence is amplified from the deposited cDNA clone using PCR oligonucleotide primers (based on the sequences presented, e.g., in at least one of SEQ ID NO:1 and SEQ ID NO:2), which anneal to the amino terminal encoding DNA sequences of the desired portion of a hOB-BP2h polypeptide and to sequences in the deposited construct 3' to the cDNA coding sequence. Additional nucleotides containing restriction sites to facilitate cloning in the pQE60 vector are added to the 5' and 3' sequences, respectively.

For cloning a hOB-BP2h polypeptide, the 5' and 3' primers have nucleotides corresponding or complementary to a portion of the coding sequence of a hOB-BP2h, e.g., as presented in at least one of SEQ ID NO:1 and SEQ ID NO:2, according to known method steps. One of ordinary skill in the art would appreciate, of course, that the point in a polypeptide coding sequence where the 5' primer begins can be varied to amplify a desired portion of the complete polypeptide shorter or longer than the mature form.

The amplified hOB-BP2h nucleic acid fragments and the vector pQE60 are digested with appropriate restriction enzymes and the digested DNAs are then ligated together. Insertion of the hOB-BP2h DNA into the restricted pQE60

-48-

vector places a hOB-BP2h polypeptide coding region including its associated stop codon downstream from the IPTG-inducible promoter and in-frame with an initiating AUG codon. The associated stop codon prevents translation of the six
5 histidine codons downstream of the insertion point.

The ligation mixture is transformed into competent *E. coli* cells using standard procedures such as those described in Sambrook, et al., 1989; Ausubel, 1987-1998. *E. coli* strain M15/rep4, containing multiple copies of the plasmid
10 pREP4, which expresses the lac repressor and confers kanamycin resistance ("Kanr"), is used in carrying out the illustrative example described herein. This strain, which is only one of many that are suitable for expressing hOB-BP2h polypeptide, is available commercially from QIAGEN,
15 Inc. Transformants are identified by their ability to grow on LB plates in the presence of ampicillin and kanamycin. Plasmid DNA is isolated from resistant colonies and the identity of the cloned DNA confirmed by restriction analysis, PCR and DNA sequencing.

20 Clones containing the desired constructs are grown overnight ("O/N") in liquid culture in LB media supplemented with both ampicillin (100 µg/ml) and kanamycin (25 µg/ml). The O/N culture is used to inoculate a large culture, at a dilution of approximately 1:25 to 1:250. The cells are
25 grown to an optical density at 600 nm ("OD600") of between 0.4 and 0.6. Isopropyl-b-D-thiogalactopyranoside ("IPTG") is then added to a final concentration of 1 mM to induce transcription from the lac repressor sensitive promoter, by inactivating the lacI repressor. Cells subsequently are
30 incubated further for 3 to 4 hours. Cells then are harvested by centrifugation.

The cells are then stirred for 3-4 hours at 4°C in 6M guanidine-HCl, pH8. The cell debris is removed by

-49-

centrifugation, and the supernatant containing the hOB-BP2h is dialyzed against 50 mM Na-acetate buffer pH6, supplemented with 200 mM NaCl. Alternatively, a polypeptide can be successfully refolded by dialyzing it against 500 mM NaCl, 20% glycerol, 25 mM Tris/HCl pH7.4, containing protease inhibitors.

If insoluble protein is generated, the protein is made soluble according to known method steps. After renaturation the polypeptide is purified by ion exchange, hydrophobic interaction and size exclusion chromatography. Alternatively, an affinity chromatography step such as an antibody column is used to obtain pure hOB-BP2h polypeptide. The purified polypeptide is stored at 4°C or frozen at -40°C to -120°C.

Example 2: Cloning and Expression of an hOB-BP2h Polypeptide in a Baculovirus Expression System

In this illustrative example, the plasmid shuttle vector pA2 GP is used to insert the cloned DNA encoding the mature polypeptide into a baculovirus to express a hOB-BP2h polypeptide, using a baculovirus leader and standard methods as described in Summers, et al., A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agricultural Experimental Station Bulletin No. 1555 (1987). This expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV) followed by the secretory signal peptide (leader) of the baculovirus gp67 polypeptide and convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from E. coli under control of a weak

-50-

Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate viable virus that expresses the cloned polynucleotide.

Other baculovirus vectors are used in place of the vector above, such as pAc373, pVL941 and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow, et al., Virology 170:31-39.

The cDNA sequence encoding the mature hOB-BP2h polypeptide in the deposited or other clone, lacking the AUG initiation codon and the naturally associated nucleotide binding site, is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene. Non-limiting examples include 5' and 3' primers having nucleotides corresponding or complementary to a portion of the coding sequence of a hOB-BP2h polypeptide, e.g., as presented in at least one of SEQ ID NO:1 and SEQ ID NO:2, according to known method steps.

The amplified fragment is isolated from a 1% agarose gel using a commercially available kit (e.g., "Geneclean," BIO 101 Inc., La Jolla, CA). The fragment then is then digested with the appropriate restriction enzyme and again is purified on a 1% agarose gel. This fragment is designated herein "F1".

The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1%

-51-

agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, CA). This vector DNA is designated herein "V1".

Fragment F1 and the dephosphorylated plasmid V1 are
5 ligated together with T4 DNA ligase. E. coli HB101 or other
suitable E. coli hosts such as XL-1 Blue (Stratagene Cloning
Systems, La Jolla, CA) cells are transformed with the
ligation mixture and spread on culture plates. Bacteria are
identified that contain the plasmid with the human hOB-BP2h
10 gene using the PCR method, in which one of the primers that
is used to amplify the gene and the second primer is from
well within the vector so that only those bacterial colonies
containing the hOB-BP2h gene fragment will show
amplification of the DNA. The sequence of the cloned
15 fragment is confirmed by DNA sequencing. This plasmid is
designated herein pBac hOB-BP2h .

Five µg of the plasmid pBachOB-BP2h is co-transfected
with 1.0 µg of a commercially available linearized
baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen,
20 San Diego, CA), using the lipofection method described by
Felgner, et al., Proc. Natl. Acad. Sci. USA 84:7413-7417
(1987). 1 µg of BaculoGold™ virus DNA and 5 µg of the
plasmid pBac hOB-BP2h are mixed in a sterile well of a
microtiter plate containing 50 µl of serum-free Grace's
25 medium (Life Technologies, Inc., Rockville, MD).
Afterwards, 10 µl Lipofectin plus 90 µl Grace's medium are
added, mixed and incubated for 15 minutes at room
temperature. Then the transfection mixture is added drop-
wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm
30 tissue culture plate with 1 ml Grace's medium without serum.
The plate is rocked back and forth to mix the newly added
solution. The plate is then incubated for 5 hours at 27°C.
After 5 hours the transfection solution is removed from the

-52-

plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. The plate is put back into an incubator and cultivation is continued at 27°C for four days.

5 After four days the supernatant is collected and a plaque assay is performed, according to known methods. An agarose gel with "Blue Gal" (Life Technologies, Inc., Rockville, MD) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-
10 stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies, Inc., Rockville, MD, page 9-10). After appropriate incubation, blue stained plaques are picked with
15 a micropipettor tip (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 µl of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days
20 later the supernatants of these culture dishes are harvested and then they are stored at 4°C. The recombinant virus is called V-hOB-BP2h.

To verify the expression of the hOB-BP2h gene, Sf9
cells are grown in Grace's medium supplemented with 10%
25 heat-inactivated FBS. The cells are infected with the recombinant baculovirus V-hOB-BP2h at a multiplicity of infection ("MOI") of about 2. Six hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available, e.g., from Life
30 Technologies, Inc., Rockville, MD). If radiolabeled polypeptides are desired, 42 hours later, 5 mCi of 35S-methionine and 5 mCi 35S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and

-53-

then they are harvested by centrifugation. The polypeptides in the supernatant as well as the intracellular polypeptides are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled). Microsequencing of the amino acid sequence of the amino terminus of purified polypeptide can be used to determine the amino terminal sequence of the mature polypeptide and thus the cleavage point and length of the secretory signal peptide.

Example 3: Cloning and Expression of hOB-BP2h in Mammalian Cells

A typical mammalian expression vector contains at least one promoter element, which mediates the initiation of transcription of mRNA, the polypeptide coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRS) from Retroviruses, e.g., RSV, HTLV, HIV and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter). Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pIRESneo, pRetro-Off, pRetro-On, PLXSN, or pLNCX (Clontech Labs, Palo Alto, CA), pcDNA3.1 (+/-), pcDNA/Zeo (+/-) or pcDNA3.1/Hygro (+/-) (Invitrogen), PSVL and PMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146) and pBC12MI (ATCC 67109). Mammalian host cells that could be used include human Hela 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and

-54-

CV 1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

Alternatively, the gene is expressed in stable cell lines that contain the gene integrated into a chromosome.

5 The co-transfection with a selectable marker such as dhfr, gpt, neomycin, or hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the encoded polypeptide. The DHFR (dihydrofolate reductase) marker is useful to develop cell lines that carry several hundred or even several thousand copies of the gene of interest. Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy, et al., Biochem. J. 227:277-279 (1991); Bebbington, et al., 10 Bio/Technology 10:169-175 (1992)). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for 15 the production of polypeptides.

The expression vectors pC1 and pC4 contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen, et al., Molec. Cell. Biol. 5:438-447 (1985)) plus a fragment of the CMV-enhancer (Boshart, et al., Cell 41:521-530 (1985)).

25 Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors contain in addition the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene.

30 **Example 3(a): Cloning and Expression in COS Cells**

The expression plasmid, phOB-BP2h HA, is made by cloning a cDNA encoding hOB-BP2h into the expression vector

-55-

pcDNAI/Amp or pcDNAIII (which can be obtained from Invitrogen, Inc.).

The expression vector pcDNAI/amp contains: (1) an E. coli origin of replication effective for propagation in E. coli and other prokaryotic cells; (2) an ampicillin resistance gene for selection of plasmid-containing prokaryotic cells; (3) an SV40 origin of replication for propagation in eucaryotic cells; (4) a CMV promoter, a polylinker, an SV40 intron; (5) several codons encoding a hemagglutinin fragment (i.e., an "HA" tag to facilitate purification) or HIS tag (see, e.g, Ausubel, supra) followed by a termination codon and polyadenylation signal arranged so that a cDNA can be conveniently placed under expression control of the CMV promoter and operably linked to the SV40 intron and the polyadenylation signal by means of restriction sites in the polylinker. The HA tag corresponds to an epitope derived from the influenza hemagglutinin polypeptide described by Wilson, et al., Cell 37:767-778 (1984). The fusion of the HA tag to the target polypeptide allows easy detection and recovery of the recombinant polypeptide with an antibody that recognizes the HA epitope. pcDNAIII contains, in addition, the selectable neomycin marker.

A DNA fragment encoding the hOB-BP2h is cloned into the polylinker region of the vector so that recombinant polypeptide expression is directed by the CMV promoter. The plasmid construction strategy is as follows. The hOB-BP2h cDNA of the deposited clone is amplified using primers that contain convenient restriction sites, much as described above for construction of vectors for expression of hOB-BP2h in E. coli. Non-limiting examples of suitable primers include those based on the coding sequences presented in at least one of SEQ ID NO:1 and SEQ ID NO:2, as they encode hOB-BP2h polypeptides as described herein.

-56-

The PCR amplified DNA fragment and the vector, pcDNAI/Amp, are digested with suitable restriction enzyme(s) and then ligated. The ligation mixture is transformed into E. coli strain SURE (available from Stratagene Cloning Systems, 11099 North Torrey Pines Road, La Jolla, CA 92037), and the transformed culture is plated on ampicillin media plates which then are incubated to allow growth of ampicillin resistant colonies. Plasmid DNA is isolated from resistant colonies and examined by restriction analysis or other means for the presence of the hOB-BP2h-encoding fragment.

For expression of recombinant hOB-BP2h, COS cells are transfected with an expression vector, as described above, using DEAE-DEXTRAN, as described, for instance, in Sambrook, et al., Molecular Cloning: a Laboratory Manual, Cold Spring Laboratory Press, Cold Spring Harbor, New York (1989). Cells are incubated under conditions for expression of hOB-BP2h by the vector.

Expression of the hOB-BP2h-HA fusion polypeptide is detected by radiolabeling and immunoprecipitation, using methods described in, for example Harlow, et al., Antibodies: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988). To this end, two days after transfection, the cells are labeled by incubation in media containing ³⁵S-cysteine for 8 hours. The cells and the media are collected, and the cells are washed and lysed with detergent-containing RIPA buffer: 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% DOC, 50 mM TRIS, pH 7.5, as described by Wilson, et al. cited above. Proteins are precipitated from the cell lysate and from the culture media using an HA-specific monoclonal antibody. The precipitated polypeptides then are analyzed by SDS-PAGE and autoradiography. An expression product of the expected size

-57-

is seen in the cell lysate, which is not seen in negative controls.

Example 3(b): Cloning and Expression in CHO Cells

5 The vector pC4 is used for the expression of hOB-BP2h polypeptide. Plasmid pC4 is a derivative of the plasmid pSV2-dhfr (ATCC Accession No. 37146). The plasmid contains the mouse DHFR gene under control of the SV40 early promoter. Chinese hamster ovary- or other cells lacking
10 dihydrofolate activity that are transfected with these plasmids are selected by growing the cells in a selective medium (alpha minus MEM, Life Technologies) supplemented with the chemotherapeutic agent methotrexate. The amplification of the DHFR genes in cells resistant to
15 methotrexate (MTX) has been well documented (see, e.g., F. W. Alt, et al., J. Biol. Chem. 253:1357-1370 (1978); J. L. Hamlin and C. Ma, Biochem. et Biophys. Acta 1097:107-143 (1990); and M. J. Page and M. A. Sydenham, Biotechnology 9:64-68 (1991)). Cells grown in increasing concentrations
20 of MTX develop resistance to the drug by overproducing the target enzyme, DHFR, as a result of amplification of the DHFR gene. If a second gene is linked to the DHFR gene, it is usually co-amplified and over-expressed. It is known in the art that this approach is used to develop cell lines
25 carrying more than 1,000 copies of the amplified gene(s). Subsequently, when the methotrexate is withdrawn, cell lines are obtained which contain the amplified gene integrated into one or more chromosome(s) of the host cell.

Plasmid pC4 contains for expressing the gene of
30 interest the strong promoter of the long terminal repeat (LTR) of the Rous Sarcoma Virus (Cullen, et al., Molec. Cell. Biol. 5:438-447 (1985)) plus a fragment isolated from the enhancer of the immediate early gene of human

-58-

cytomegalovirus (CMV) (Boshart, et al., Cell 41:521-530 (1985)). Downstream of the promoter are BamHI, XbaI, and Asp718 restriction enzyme cleavage sites that allow integration of the genes. Behind these cloning sites the plasmid contains the 3' intron and polyadenylation site of the rat preproinsulin gene. Other high efficiency promoters can also be used for the expression, e.g., the human b-actin promoter, the SV40 early or late promoters or the long terminal repeats from other retroviruses, e.g., HIV and HTLVII. Clontech's Tet-Off and Tet-On gene expression systems and similar systems are used to express the hOB-BP2h in a regulated way in mammalian cells (M. Gossen, and H. Bujard, Proc. Natl. Acad. Sci. USA 89: 5547-5551 (1992)). For the polyadenylation of the mRNA other signals, e.g., from the human growth hormone or globin genes is used as well. Stable cell lines carrying a gene of interest integrated into the chromosomes can also be selected upon co-transfection with a selectable marker such as gpt, G418 or hygromycin. It is advantageous to use more than one selectable marker in the beginning, e.g., G418 plus methotrexate.

The plasmid pC4 is digested with restriction enzymes and then dephosphorylated using calf intestinal phosphatase by procedures known in the art. The vector is then isolated from a 1% agarose gel.

The DNA sequence encoding the complete hOB-BP2h polypeptide is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' sequences of the gene. Non-limiting examples include 5' and 3' primers having nucleotides corresponding or complementary to a portion of the coding sequence of a hOB-BP2h, e.g., as presented in at least one of SEQ ID NO:1 and SEQ ID NO:2, according to known method steps.

-59-

The amplified fragment is digested with suitable endonucleases and then purified again on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. E. coli HB101 or XL-1 Blue
5 cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC4 using, for instance, restriction enzyme analysis.

Chinese hamster ovary (CHO) cells lacking an active DHFR gene are used for transfection. 5 µg of the expression
10 plasmid pC4 is cotransfected with 0.5 µg of the plasmid pSV2-neo using lipofectin. The plasmid pSV2neo contains a dominant selectable marker, the neo gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM
15 supplemented with 400 µg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 400 µg/ml G418. After about 10-14 days single clones are trypsinized and then
20 seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of
25 methotrexate (1 µM, 2 µM, 5 µM, 10 µM, 20 µM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 µM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reverse phase HPLC analysis.

-60-

**Example 4: Cloning and Construction of hOB-BP2h-ECD
Immunoglobulin Fusion Proteins (hOB-BP2h-ECD-Fc)**

5 A. PREPARATION OF hOB-BP2h-ECD-Fc FUSION PROTEINS

The extracellular domain (ECD) portion of hOB-BP2h is prepared as a fusion protein coupled to an immunoglobulin constant region (Fc), resulting in a hOB-BP2h-ECD-Fc polypeptide. The immunoglobulin constant region may contain genetic modifications including those which reduce or eliminate effector activity inherent in the immunoglobulin structure. (See, e.g., PCT Publication No. WO88/07089, published September 22, 1988). Briefly, PCR overlap extension is applied to join DNA encoding the ECD portion of a hOB-BP2h polypeptide to DNA encoding the hinge, CH2 and CH3 regions of human IgG1. This is accomplished as described in the following subsections.

20 B. PREPARATION OF GENE FUSIONS

A DNA fragment corresponding to the DNA sequences encoding the hOB-BP2h-ECD or a portion thereof is prepared by polymerase chain reaction (PCR). A cDNA encoding hOB-BP2h can serve as the template for amplifying the hOB-BP2h-ECD or portion thereof. PCR amplification is performed to generate a DNA fragment which encodes the hOB-BP2h-ECD (amino acid residues 1-360 of SEQ ID NO:3 or amino acid residues 1-487 of SEQ ID NO:4) or a portion thereof (i.e., amino acid residues 41-360 of SEQ ID NO:3 or amino acid residues 41-487 of SEQ ID NO:4).

In a second PCR reaction, a set of primers is designed to amplify the IgG constant region (i.e., the hinge, CH2,

-61-

and CH3, domains) such that the reverse primer has a unique restriction site and the sequence of the forward primer has a 5' terminus that is complementary to the 5' terminal region of the reverse primer used in the hOB-BP2h-ECD amplification and allowing the open reading frame in the hOB-BP2h-ECD encoding nucleotide sequence to continue throughout the length of the IgG nucleotide sequence. The sequence of human IgG1 is obtained through Genbank (accession: HUMIGCC4; Takahashi et. al (vol.29, 671-679, 1982). This is compiled into exons and a region upstream of the natural hinge region is chosen as the fusion site. The 5' primer is designed to include an overlap for the hOB-BP2h-ECD amplicon and yet amplify DNA encoding the Fc region of human IgG1. The 3' primer is designed to amplify the DNA molecule encoding the Fc region of human IgG1 while incorporating both a translation stop codon and a restriction site to facilitate cloning into the amplification product. The target DNA in this reaction is human genomic DNA encoding IgG heavy chain (Ellison et al., 1982, Nuc. Acids. Res. 10:4071-4079) and is amplified using Human Lymph Node QUICK-Clone™ cDNA purchased from Clontech (cat# 7164-1) as template.

PCR reactions are prepared in 100 µl final volume composed of Pfu polymerase and buffer (Stratagene) containing primers (1 µM each), dNTPs (200 µM each), and 1ng of template DNA.

The complete hOB-BP2h-ECD-Fc fusion segment is prepared by performing another PCR reaction. The purified products of the two PCR reactions above is mixed, denatured (95°C, 1 minute) and then renatured (54°C, 30 seconds) to allow complementary ends of the two fragments to anneal. The strands then are filled in using dNTPs and Taq polymerase and the entire fragment is amplified using the forward PCR

-62-

primer of the first PCR reaction and the reverse PCR primer of the second PCR reaction. For convenience of cloning into the expression vector, the resulting fragment is then cleaved with restriction enzymes which recognize the unique sites incorporated into the forward PCR primer of the first PCR reaction and the reverse PCR primer of the second PCR reaction. The digested fragment is gel purified and then ligated into an expression vector, such as pIG1, that has also been treated with the same restriction enzymes and calf intestinal alkaline phosphatase (CIAP). The ligation reaction is used to transform DH5 α and recombinant plasmids are identified. Plasmid DNA from isolated transformants is prepared and the insert contained within the recombinant plasmid is sequenced to confirm the correctness of the hOB-BP2h-ECD-Fc fusion construct.

C. ISOLATION OF STABLE CLONES

Cell lines including, but not limited to, 293T cells are transformed with recombinant plasmids containing the hOB-BP2h-ECD-Fc fusion construct. For example, 293T cells are grown and a transient transfection utilizing lipofectamine (GIBCO-BRL) is performed. Characterization of the supernatant revealing a protein of the size one would expect for either a monomer or a dimer of the hOB-BP2h-ECD-Fc, can confirm the integrity of the construct. The expression of the protein can also be confirmed by a Western utilizing an antibody to human IgG1.

To produce cell lines stably expressing the hOB-BP2h-ECD-Fc fusion protein, a cell line such as, but not limited to, the Syrian hamster cell line AV12-RGT18 is transfected with the hOB-BP2h-ECD-Fc fusion protein construct by a transfection method such as, but not limited to, the calcium

- 63 -

chloride precipitation method (Promega). Two days after the transfection the cells are washed and then trypsinized. The cells are collected and resuspended in 10 ml of the appropriate media. The transfected cells are plated onto gridded Falcon 3025 plates at 1/10, 1/50, and 1/250 in a final volume of 35 ml. The media may contain methotrexate at 250 nM concentration. pIG1 contains a copy of the DHFR gene and when amplified will convey methotrexate resistance on the transfected cells. After two to five days, colonies are identified in the 1/50 and 1/250 dilution platings, transferred to microtiter plates, and grown under selection. The ability of these clones to produce the hOB-BP2h-ECD-Fc protein is examined in serum free media. Single clones producing hOB-BP2h-ECD-Fc protein are isolated and grown up in 80 roller bottles. The media is collected and the hOB-BP2h-ECD-Fc fusion protein is isolated as described below.

Those skilled in the art are aware of various considerations which influence the choice of expression vector into which the hOB-BP2h-ECD-Fc fusion segment is cloned, such as the identity of the host organism and the presence of elements necessary for achieving desired transcriptional and translational control. For example, if transient expression is desired, the hOB-BP2h-ECD-Fc fusion segment generated supra is cloned into the expression vector pcDNA-1 (Invitrogen). Alternatively, stable expression of the fusion protein is achieved by cloning the hOB-BP2h-ECD-Fc fusion segment into the expression vector pcDNA-3 (Invitrogen). Alternatively, hOB-BP2h-ECD-Fc fusion proteins is generated using an expression vector such as the CD5-IgG1 vector (described by Aruffo et al., (1990), Cell, 61:1303-1313), which already contains the IgG constant region. According to this method, the DNA fragment encoding the hOB-BP2h-ECD is generated in a PCR reaction so that the open reading frame encoding the hOB-BP2h-ECD is continuous

-64-

and in frame with that encoding the IgG constant region. For example, the extracellular domains (including signal peptides) of hOB-BP2h-ECD are PCR amplified. Each forward primer above contains a restriction site and each reverse
5 primer above contains a restriction site. After amplification using the hOB-BP2h-ECD cDNA as a template, the resulting PCR fragment is cloned into the CD5-IgG vector (Aruffo et al., (1990), Cell). The resulting vector is transiently transfected into COS cells and conditioned media
10 is generated. Immunoprecipitation (IP) of the conditioned media with protein A and analysis by SDS PAGE reveals whether the desired protein is expressed. To improve expression of the human HOB-BP2H-ECD-Fc fusion, primers are designed which amplify the extracellular domain of hOB-BP2H
15 (without the signal peptide) and this fragment is coligated with sequences encoding other signal-peptides such as that from mouse hOB-BP2h into the CD5-IgG vector. After amplification, restriction enzyme digestion, and subcloning, the resulting construct is transiently expressed in COS
20 cells. IP and SDS-PAGE analysis of the resulting conditioned media will show whether expression of the human hOB-BP2h-ECD-Fc fusion was successful. An alternative method for enhancing the expression of immunoglobulin fusion proteins, involves insertion of the hOB-BP2h-ECD (not
25 including the signal peptide) into the CD5-IgG1 vector in such a manner so that the CD5 signal peptide is fused to the mature hOB-BP2h-ECD. Such a signal peptide fusion has been shown to improve expression of immunoglobulin fusion proteins.

30

C. PREPARATION OF MODIFIED CH2 DOMAINS

The nucleotide sequence of the hOB-BP2h-ECD-Fc gene fusions described supra, is modified to replace cysteine

-65-

residues in the hinge region with serine residues and/or amino acids within the CH2 domain which are believed to be required for IgG binding to Fc receptors and complement activation.

5 Modification of the CH2 domain to replace amino acids thought to be involved in binding to Fc receptor is accomplished as follows. The plasmid construct generated supra, provides the template for modifications of the hOB-BP2h-ECD-IgC γ 1 CH2 domain. This template is PCR amplified
10 using the forward PCR primer described in the first PCR reaction supra and a reverse primer designed such that it is homologous to the 5' terminal portion of the CH2 domain of IgG1 except for five nucleotide substitutions designed to change amino acids 234, 235, and 237 (Canfield, S.M. and
15 Morrison, S.L., (1991), J. Exp. Med. 173:1483-1491) from Leu to Ala, Leu to Glu, and Gly to Ala, respectively. Amplification with these PCR primers will yield a DNA fragment consisting of a modified portion of the CH2 domain. In a second PCR reaction, the template is PCR amplified with
20 the reverse primer used in the second PCR reaction supra, and a forward primer which is designed such that it is complementary to the Ig portion of the molecule and contains the five complementary nucleotide changes necessary for the CH2 amino acid replacements. PCR amplification with these
25 primers will yield a fragment consisting of the modified portion of the CH2 domain, an intron, the CH3 domain, and 3' additional sequences. The complete hOB-BP2h-ECD-IgC γ 1 segment consisting of a modified CH2 domain is prepared by an additional PCR reaction. The purified products of the
30 two PCR reactions above are mixed, denatured (95°C, 1 minute) and then renatured (54°C, 30 seconds) to allow complementary ends of the two fragments to anneal. The strands are filled in using dNTP and Taq polymerase and the

-66-

entire fragment is amplified using the forward PCR primer of the first PCR reaction and the reverse PCR primer of the second PCR reaction. For convenience of cloning into the expression vector, the resulting fragment is then cleaved with restriction enzymes which recognize those sites specific to the forward PCR primer of the first PCR reaction and the reverse PCR primer of the second PCR reaction. This digested fragment is then cloned into an expression vector that was also treated with these restriction enzymes.

Sequence analysis is used to confirm structure and the construct is used to transfect COS cells to test transient expression. hIgG ELISA is used to measure/confirm transient expression levels approximately equal to 100ng protein/ml cell supernatant for the construct. CHO is one but not the only example of a cell line that is transfected for permanent expression of the fusion proteins.

Example 5: Isolation of a high-producing hOB-BP2h-ECD-Fc clone from AV12 RGT18 transfectants

The vector pIG1 encodes resistance to methotrexate. In addition, the vector is designed to contain a gene encoding a fluorescent protein, GFP, on the same transcript and immediately 3' to an inserted hOB-BP2h-ECD-Fc cDNA. In this case, high level expression of GFP would require a high level of expression of the hOB-BP2h-ECD-Fc mRNA. Thus, highly fluorescent clones would have a greater probability of producing high levels of hOB-BP2h-ECD-Fc. After transfecting AV12 RGT18 cells with either pIG1-hOB-BP2h-ECD and pIG1-hOB-BP2h-ECD-Fc cells resistant to 250 nM methotrexate are selected and pooled. The pool of resistant clones is subjected to fluorescence assisted cell sorting (FACS), and cells having fluorescence values in the top 5%

-67-

of the population are sorted into a pool. This highly fluorescent pool is subjected to three successive sorting cycles. Pools and individual clones from the second and third cycles are analyzed for hOB-BP2h-ECD production by SDS-PAGE. Pools or clones expressing the hOB-BP2h-ECD proteins at the highest level judged from Coomassie staining are used for scale-up and purification of the expressed protein.

Example 6: Purification of hOB-BP2h-ECD-Fc Fusion Proteins from AV12 media

AV12 cells transformed with a vector containing a cDNA insert encoding a hOB-BP2h-ECD-Fc fusion protein are grown in culture bottles until confluent. Media is collected, concentrated approximately 20-fold, and clarified by centrifugation. The media concentrate is pumped onto a Ni loaded iminodiacetic acid column. The column is washed with 100 mM sodium phosphate, 100 mM sodium chloride buffer (pH 7.5). Bound protein is eluted with a pH gradient from pH 7.5 to 4.25.

Fractions containing the hOB-BP2h-ECD-Fc fusion protein is pooled, diluted 1:1 with 50 mM sodium phosphate (pH 5.6) and pumped onto a cation exchange column (TSK-SP 5PW). The column is washed with 50 mM sodium phosphate (pH 5.6) and bound protein eluted with a gradient from 0 to 0.5 M sodium chloride. Fractions containing hOB-BP2h-ECD-Fc fusion are pooled and dialyzed into phosphate buffered saline (pH 7.5).

The identity of the protein is confirmed by digesting the protein with trypsin and analyzing the resulting peptides by mass spectroscopy and tandem MS/MS analysis.

-68-

Example 7: Tissue Distribution of hOB-BP2h mRNA Expression

Northern blot analysis is carried out to examine hOB-BP2h gene expression in human tissues, using methods described by, among others, Sambrook, et al., cited above.

5 A cDNA probe containing the entire nucleotide sequence of a hOB-BP2h polypeptide (e.g., SEQ ID NO:1 or SEQ ID NO:2) is labeled with ^{32}P using the RediprimeTM DNA labeling system (Amersham Life Science), according to the manufacturer's instructions. After labeling, the probe is purified using a
10 CHROMA SPIN-100TM column (Clontech Laboratories, Inc.), according to the manufacturer's protocol number PT1200-1. The purified and labeled probe is used to examine various human tissues for hOB-BP2h mRNA.

Multiple Tissue Northern (MTN) blots containing various
15 human tissues (H) or human immune system tissues (IM) are obtained from Clontech and are examined with the labeled probe using ExpressHyb hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted
20 and exposed to film at -70°C overnight, and films developed according to standard procedures. The results show hOB-BP2h polypeptides to be selectively expressed in at least one of hemic, immune, and digestive system and other tissues.

25 **EXAMPLE 8: Directed Mutagenesis of hOB-BP2h polypeptides to provide DNA encoding specified substitutions, insertions or deletions of SEQ ID NO:3, 4, or 5 Using the Polymerase Chain Reaction**

30 The polymerase chain reaction (PCR) is used for the enzymatic amplification and direct sequencing of small quantities of nucleic acids (see, e.g., Ausubel, supra, section 15) to provide specified substitutions, insertions or deletions in DNA encoding a hOB-BP2h polypeptide of the
35 present inventions (e.g., SEQ ID NO:1, SEQ ID NO:2, or any

-69-

sequence described herein), as presented herein, to provide a hOB-BP2h polypeptide sequence of interest including at least one substitution, insertion or deletion selected from the group consisting of 3P, 4L, 8P, 9L, 11W, 15L, 16Q, 17E, 18K, 19P, 20V, 21Y, 22E, 23L, 24Q, 27K, 30T, 32Q, 37V, 38L, 47W, 48R, 49S, 51Y, 52S, 54P, 56L, 58V, 70A, 71E, 72V, 77N, 78P, 79D, 81R, 83K, 84P, 85E, 87Q, 91R, 93L, 96V, 97Q, 99K, 104S, 106G, 109R, 111E, 113T, 114G, 115S, 124R, 125D, 127K, 129S, 130Y, 131Q, 132Q, 133N, 134K, 135L, 136N, 138E, 141V, 143S, 143I, 144F, 144E, 145T, 210N, and 252A of SEQ ID NO:3, or 3P, 4L, 8P, 9L, 11W, 15L, 16Q, 17E, 18K, 19P, 20V, 21Y, 22E, 23L, 24Q, 27K, 30T, 32Q, 37V, 38L, 47W, 48R, 49S, 51Y, 52S, 54P, 56L, 58V, 70A, 71E, 72V, 77N, 78P, 79D, 81R, 83K, 84P, 85E, 87Q, 91R, 93L, 96V, 97Q, 99K, 104S, 106G, 109R, 111E, 113T, 114G, 115S, 124R, 125D, 127K, 129S, 130Y, 131Q, 132Q, 133N, 134K, 135L, 136N, 138E, 141A, 143T, 143I, 144Q, 144E, 145K, 152D, 194D, 386S, 387L, 389Q, 405R, 408F, 409R, 411R, 417C, 419R, 421E, 423K, 424P, 432G, 435K, 437N, 438G, 450I, 458D, 460K, 461V, 462S, 464K, 468I, 469Y, 471S, and 476V of SEQ ID NO:4.

This technology is used as a quick and efficient method for introducing any desired sequence change into the DNA of interest.

Unit 8.5 of Ausubel, supra, contains two basic protocols for introducing base changes into specific DNA sequences. Basic Protocol 1, as presented in the first section 8.5 of Ausubel, supra (entirely incorporated herein by reference), describes the incorporation of a restriction site and Basic Protocol 2, as presented below and in the second section of Unit 8.5 of Ausubel, supra, details the generation of specific point mutations (all of the following references in this example are to sections of Ausubel et al., eds., Current Protocols in Molecular Biology, Wiley Interscience, New York (1987-1999)). An alternate protocol

-70-

describes generating point mutations by sequential PCR steps. Although the general procedure is the same in all three protocols, there are differences in the design of the synthetic oligonucleotide primers and in the subsequent
5 cloning and analyses of the amplified fragments.

The PCR procedure described here can rapidly, efficiently, and reproducibly introduce any desired change into a DNA fragment. It is similar to the oligonucleotide-directed mutagenesis method described in UNIT 8.1, but does
10 not require the preparation of a uracil-substituted DNA template.

The main disadvantage of PCR-generated mutagenesis is related to the fidelity of the Taq DNA polymerase. The mutation frequency for Taq DNA polymerase was initially
15 estimated to be as high as 1/5000 per cycle (Saiki et al., 1988). This means that the entire amplified fragment must be sequenced to be sure that there are no Taq-derived mutations. To reduce the amount of sequencing required, it is best to introduce the mutation by amplifying as small a
20 fragment as possible. With rapid and reproducible methods of double-stranded DNA sequencing (UNIT 7.4), the entire amplified fragment can usually be sequenced from a single primer. If the fragment is somewhat longer, it is best to subclone the fragment into an M13-derived vector, so that
25 both forward and reverse primers is used to sequence the amplified fragment.

If there are no convenient restriction sites flanking the fragment of interest, the utility of this method is somewhat reduced. Many researchers prefer the mutagenesis
30 procedure in UNIT 8.1 to avoid excessive sequencing.

A full discussion of critical parameters for PCR amplification is found in UNIT 15.1.

-71-

Anticipated Results

Each of the procedures presented here has a 100% efficiency rate. All or substantially all of the cloned, amplified fragments will contain the mutation corresponding to the synthesized oligonucleotide.

Literature Cited

Saiki, R.K., Gelfand, D.H., Stoffel, S., Scharf, S.J., Higuchi, R., Horn, G.T., Mullis, K.B., and Erlich, H.A. 1988. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487-491.

BASIC PROTOCOL (2): INTRODUCTION OF POINT MUTATIONS BY PCR

In this protocol, synthetic oligonucleotides are designed to incorporate a point mutation at one end of an amplified fragment. Following PCR, the amplified fragments are made blunt-ended by treatment with Klenow fragment. These fragments are then ligated and subcloned into a vector to facilitate sequence analysis. This procedure is summarized in Figure 8.5.2 of Ausubel, supra.

Materials

DNA sample to be mutagenized
Klenow fragment of E. coli DNA polymerase I (UNIT 3.5 of Ausubel, supra)
Appropriate restriction endonuclease (Table 8.5.1)
Additional reagents and equipment for synthesis and purification of oligonucleotides (UNITS 2.11 & 2.12), phosphorylation of oligonucleotides (UNIT 3.10), electrophoresis of DNA on nondenaturing agarose and low gelling/melting agarose gels (UNITS 2.5A & 2.6), restriction endonuclease digestion (UNIT 3.1), ligation of DNA fragments (UNIT 3.16), transformation of E. coli (UNIT 1.8), plasmid DNA miniprep (UNIT 1.6), and DNA sequence analysis (UNIT 7.4).

-72-

Prepare the template DNA and oligonucleotide primers

Prepare template DNA (see Basic Protocol 1, steps 1 and 2). Synthesize (UNIT 2.11) and purify (UNIT 2.12) the oligonucleotide primers (primers 3 and 4 in Fig. 8.5.2B).

- 5 The oligonucleotide primers must be homologous to the template DNA for more than 15 bases. No four-base "clamp" sequence is added to these primers. The primer sequences are based on a DNA encoding the hOB-BP2h polypeptide sequence of interest including at least one substitution, insertion or deletion selected from the group consisting of
- 10 3P, 4L, 8P, 9L, 11W, 15L, 16Q, 17E, 18K, 19P, 20V, 21Y, 22E, 23L, 24Q, 27K, 30T, 32Q, 37V, 38L, 47W, 48R, 49S, 51Y, 52S, 54P, 56L, 58V, 70A, 71E, 72V, 77N, 78P, 79D, 81R, 83K, 84P, 85E, 87Q, 91R, 93L, 96V, 97Q, 99K, 104S, 106G, 109R, 111E,
- 15 113T, 114G, 115S, 124R, 125D, 127K, 129S, 130Y, 131Q, 132Q, 133N, 134K, 135L, 136N, 138E, 141V, 143S, 143I, 144F, 144E, 145T, 210N, and 252A of SEQ ID NO:3, or 3P, 4L, 8P, 9L, 11W, 15L, 16Q, 17E, 18K, 19P, 20V, 21Y, 22E, 23L, 24Q, 27K, 30T, 32Q, 37V, 38L, 47W, 48R, 49S, 51Y, 52S, 54P, 56L, 58V,
- 20 70A, 71E, 72V, 77N, 78P, 79D, 81R, 83K, 84P, 85E, 87Q, 91R, 93L, 96V, 97Q, 99K, 104S, 106G, 109R, 111E, 113T, 114G, 115S, 124R, 125D, 127K, 129S, 130Y, 131Q, 132Q, 133N, 134K, 135L, 136N, 138E, 141A, 143T, 143I, 144Q, 144E, 145K, 152D, 194D, 386S, 387L, 389Q, 405R, 408F, 409R, 411R, 417C, 419R,
- 25 421E, 423K, 424P, 432G, 435K, 437N, 438G, 450I, 458D, 460K, 461V, 462S, 464K, 468I, 469Y, 471S, and 476V of SEQ ID NO:4.

Phosphorylate the 5' end of the oligonucleotides (UNIT 3.10). This step is necessary because the 5' end of the oligonucleotide will be used directly in cloning.

- 30 Amplify DNA and prepare blunt-end fragments

Amplify the template DNA (see Basic Protocol 1, steps 5 and 6). After the final extension step, add 5 U Klenow fragment to the reaction mix and incubate 15 min at 30°C.

-73-

During PCR, the Taq polymerase adds an extra nontemplated nucleotide to the 3' end of the fragment. The 3'-5' exonuclease activity of the Klenow fragment is required to make the ends flush and suitable for blunt-end cloning (UNIT 3.5). Analyze and process the reaction mix (see Basic Protocol 1, steps 7 and 8). Digest half the amplified fragments with the restriction endonucleases for the flanking sequences (UNIT 3.1). Purify digested fragments on a low gelling/melting agarose gel (UNIT 2.6).

Subclone the two amplified fragments into an appropriately digested vector by blunt-end ligation (UNIT 3.16). Transform recombinant plasmid into *E. coli* (UNIT 1.8). Prepare DNA by plasmid miniprep (UNIT 1.6). Analyze the amplified fragment portion of the plasmid DNA by DNA sequencing to confirm the point mutation (UNIT 7.4). This is critical because the Taq DNA polymerase can introduce additional mutations into the fragment (see Critical Parameters).

ALTERNATE PROTOCOL: INTRODUCTION OF A POINT MUTATION BY SEQUENTIAL PCR STEPS

In this procedure, the two fragments encompassing the mutation are annealed with each other and extended by mutually primed synthesis; this fragment is then amplified by a second PCR step, thereby avoiding the blunt-end ligation required in Basic Protocol 2. This strategy is outlined in Figure 8.5.3. For materials, see Basic Protocols 1 and 2 of Ausubel, *supra*.

Prepare template DNA (see Basic Protocol 1, steps 1 and 2). Synthesize (UNIT 2.11) and purify (UNIT 2.12) the oligonucleotide primers (primers 5 and 6 in Fig. 8.5.3B) to generate a hOB-BP2h polypeptide sequence of interest including at least one substitution, insertion or deletion selected from the group consisting of 3P, 4L, 8P, 9L, 11W, 15L, 16Q, 17E, 18K, 19P, 20V, 21Y, 22E, 23L, 24Q, 27K, 30T,

-74-

32Q, 37V, 38L, 47W, 48R, 49S, 51Y, 52S, 54P, 56L, 58V, 70A,
71E, 72V, 77N, 78P, 79D, 81R, 83K, 84P, 85E, 87Q, 91R, 93L,
96V, 97Q, 99K, 104S, 106G, 109R, 111E, 113T, 114G, 115S,
124R, 125D, 127K, 129S, 130Y, 131Q, 132Q, 133N, 134K, 135L,
5 136N, 138E, 141V, 143S, 143I, 144F, 144E, 145T, 210N, and
252A of SEQ ID NO:3, or 3P, 4L, 8P, 9L, 11W, 15L, 16Q, 17E,
18K, 19P, 20V, 21Y, 22E, 23L, 24Q, 27K, 30T, 32Q, 37V, 38L,
47W, 48R, 49S, 51Y, 52S, 54P, 56L, 58V, 70A, 71E, 72V, 77N,
78P, 79D, 81R, 83K, 84P, 85E, 87Q, 91R, 93L, 96V, 97Q, 99K,
10 104S, 106G, 109R, 111E, 113T, 114G, 115S, 124R, 125D, 127K,
129S, 130Y, 131Q, 132Q, 133N, 134K, 135L, 136N, 138E, 141A,
143T, 143I, 144Q, 144E, 145K, 152D, 194D, 386S, 387L, 389Q,
405R, 408F, 409R, 411R, 417C, 419R, 421E, 423K, 424P, 432G,
435K, 437N, 438G, 450I, 458D, 460K, 461V, 462S, 464K, 468I,
15 469Y, 471S, and 476V of SEQ ID NO:4.

The oligonucleotides must be homologous to the
template for 15 to 20 bases and must overlap with one
another by at least 10 bases. The 5' end does not have a
"clamp" sequence.

20 Amplify the template DNA and generate blunt-end
fragments (see Basic Protocol 2, steps 4 and 5). Purify the
fragments by nondenaturing agarose gel electrophoresis (UNIT
2.5A). Resuspend in TE buffer at 1 ng/ul.

Carry out second PCR amplification. Combine the
25 following in a 500-ul microcentrifuge tube:
10 ul (10 ng) each amplified fragment
1 ul (500 ng) each flanking sequence primer (each 1 uM
final)
10 ul 10x amplification buffer
30 10 ul 2 mM 4dNTP mix
H₂O to 99.5 ul
0.5 ul Taq DNA polymerase (5 U/ul).

-75-

Overlay with 100 ul mineral oil. Carry out PCR for 20 to 25 cycles, using the conditions for introduction of restriction endonuclease sites by PCR (see Basic Protocol 1, step 6). Analyze and process the reaction mix (see Basic Protocol 1, Ausubel, supra, steps 7 and 8).

Digest the DNA fragment with the appropriate restriction endonuclease for the flanking sites (UNIT 3.1). Purify the digested fragment on a low gelling/melting agarose gel (UNIT 2.6). Subclone into an appropriately digested vector. Transform recombinant plasmid into E. coli (UNIT 1.8). Prepare DNA by plasmid miniprep (UNIT 1.6). Analyze the amplified fragment portion of the plasmid DNA by DNA sequencing (UNIT 7.4) to confirm the point mutation. This is critical because the Taq DNA polymerase can introduce additional mutations into the fragment (see Critical Parameters)

It will be clear that the present invention is practiced otherwise than as particularly described in the foregoing description and examples.

Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

-76-

What is claimed is:

1. An isolated nucleic acid, comprising at least
5 one hOB-BP2h polynucleotide encoding at least 90-100% of the
contiguous amino acids of a protein sequence selected from
at least one of SEQ ID NO:3, 4, or 5.

2. An isolated nucleic acid, comprising at least
10 one hOB-BP2h polynucleotide encoding at least 90-100% of the
contiguous amino acids of a protein sequence selected from
at least one of SEQ ID NO:3 or 4, further comprising at
least one mutation corresponding to at least one
substitution, insertion or deletion selected from the group
15 consisting of 3P, 4L, 8P, 9L, 11W, 15L, 16Q, 17E, 18K, 19P,
20V, 21Y, 22E, 23L, 24Q, 27K, 30T, 32Q, 37V, 38L, 47W, 48R,
49S, 51Y, 52S, 54P, 56L, 58V, 70A, 71E, 72V, 77N, 78P, 79D,
81R, 83K, 84P, 85E, 87Q, 91R, 93L, 96V, 97Q, 99K, 104S,
106G, 109R, 111E, 113T, 114G, 115S, 124R, 125D, 127K, 129S,
20 130Y, 131Q, 132Q, 133N, 134K, 135L, 136N, 138E, 141V, 143S,
143I, 144F, 144E, 145T, 210N, and 252A of SEQ ID NO:3, or
3P, 4L, 8P, 9L, 11W, 15L, 16Q, 17E, 18K, 19P, 20V, 21Y, 22E,
23L, 24Q, 27K, 30T, 32Q, 37V, 38L, 47W, 48R, 49S, 51Y, 52S,
54P, 56L, 58V, 70A, 71E, 72V, 77N, 78P, 79D, 81R, 83K, 84P,
25 85E, 87Q, 91R, 93L, 96V, 97Q, 99K, 104S, 106G, 109R, 111E,
113T, 114G, 115S, 124R, 125D, 127K, 129S, 130Y, 131Q, 132Q,
133N, 134K, 135L, 136N, 138E, 141A, 143T, 143I, 144Q, 144E,
145K, 152D, 194D, 386S, 387L, 389Q, 405R, 408F, 409R, 411R,
417C, 419R, 421E, 423K, 424P, 432G, 435K, 437N, 438G, 450I,
30 458D, 460K, 461V, 462S, 464K, 468I, 469Y, 471S, and 476V
of SEQ ID NO:4.

3. An isolated nucleic acid, comprising at least
one hOB-BP2h polynucleotide comprising a sequence at least

-77-

90-100% of the contiguous nucleotides of at least one of SEQ ID NO:1 and SEQ ID NO:2, or a complementary sequence thereof.

5 4. A composition comprising at least one isolated nucleic acid according to any of claims 1-3 and a carrier or diluent.

10 5. A recombinant vector, comprising at least one nucleic acid according to any of claims 1-3.

 6. A host cell comprising at least one recombinant vector according to claim 5.

15 7. A method for producing at least one hOB-BP2h polypeptide, comprising culturing a host cell according to claim 6 under conditions that the at least one hOB-BP2h polypeptide is expressed in detectable or recoverable amounts.

20

 8. A transgenic or chimeric non-human animal, comprising at least one isolated nucleic acid according to any of claims 1-3.

25 9. An isolated polypeptide, comprising a hOB-BP2h polypeptide comprising at least 90-100% of the contiguous amino acids of at least one amino acid sequence of SEQ ID NO:3 or SEQ ID:4.

30 10. An isolated polypeptide according to claim 9, further comprising at least one mutation corresponding to at least one substitution, insertion or deletion selected from the group consisting of 3P, 4L, 8P, 9L, 11W, 15L, 16Q, 17E, 18K, 19P, 20V, 21Y, 22E, 23L, 24Q, 27K, 30T, 32Q, 37V, 38L,

WO 00/59942

PCT/US00/06682

-78-

47W, 48R, 49S, 51Y, 52S, 54P, 56L, 58V, 70A, 71E, 72V, 77N,
78P, 79D, 81R, 83K, 84P, 85E, 87Q, 91R, 93L, 96V, 97Q, 99K,
104S, 106G, 109R, 111E, 113T, 114G, 115S, 124R, 125D, 127K,
129S, 130Y, 131Q, 132Q, 133N, 134K, 135L, 136N, 138E, 141V,
5 143S, 143I, 144F, 144E, 145T, 210N, and 252A of SEQ ID NO:3,
or 3P, 4L, 8P, 9L, 11W, 15L, 16Q, 17E, 18K, 19P, 20V, 21Y,
22E, 23L, 24Q, 27K, 30T, 32Q, 37V, 38L, 47W, 48R, 49S, 51Y,
52S, 54P, 56L, 58V, 70A, 71E, 72V, 77N, 78P, 79D, 81R, 83K,
84P, 85E, 87Q, 91R, 93L, 96V, 97Q, 99K, 104S, 106G, 109R,
10 111E, 113T, 114G, 115S, 124R, 125D, 127K, 129S, 130Y, 131Q,
132Q, 133N, 134K, 135L, 136N, 138E, 141A, 143T, 143I, 144Q,
144E, 145K, 152D, 194D, 386S, 387L, 389Q, 405R, 408F, 409R,
411R, 417C, 419R, 421E, 423K, 424P, 432G, 435K, 437N, 438G,
450I, 458D, 460K, 461V, 462S, 464K, 468I, 469Y, 471S, and
15 476V of SEQ ID NO:4 or the corresponding amino acid of SEQ
ID NO:3.

11. An isolated polypeptide comprising at least
one polypeptide comprising at least 90-100% of the
20 contiguous amino acids of at least one extracellular domain,
intracellular domain, transmembrane domain or active domain
of at least one of SEQ ID NO:3, 4, or 5.

12. A composition, comprising at least one
25 isolated polypeptide according to any of claims 8-11 and a
carrier or diluent.

13. An isolated nucleic acid probe, fragment, or
primer, comprising a hob-BP2h polynucleotide comprising a
30 sequence corresponding or complementary to at least 10
nucleotides of SEQ ID NO:1 or SEQ ID NO:2.

-79-

14. An isolated nucleic acid, comprising a nucleic acid that hybridizes under stringent conditions to a nucleic acid according to claim 13.

5 15. An antibody or at least one fragment thereof that binds an epitope specific to at least one hOB-BP2h polypeptide according to any of claims 8-11.

10 16. A host cell, expressing at least one antibody or at least one fragment thereof according to claim 15.

17. A method for producing at least one antibody, comprising culturing a host cell according to claim 16.

15 18. A method for identifying compounds that bind at least one hOB-BP2h polypeptide, comprising

(a) admixing at least one isolated hOB-BP2h polypeptide according to any of claims 8-11 with at least one test compound or composition; and

20 (b) detecting at least one binding interaction between said at least one hOB-BP2h polypeptide and the test compound or composition.

25 19. A compound or composition detected by method according to claim 18.

30 20. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 90% identical to a sequence selected from the group consisting of:

(a) a nucleotide sequence encoding a polypeptide having the complete amino acid sequence in SEQ ID NO:3, 4, or 5;

(b) a nucleotide sequence encoding a mature polypeptide having the amino acid sequence from position 41 to position

-80-

360 of SEQ ID NO:3 or from position 41 to position 487 of
SEQ ID NO:4;

(c) a nucleotide sequence encoding the soluble
extracellular domain of a polypeptide having the amino acid
5 sequence as in positions 1-360 of SEQ ID NO:3 or positions
1-487 of SEQ ID NO:4; and

(d) a nucleotide sequence complementary to any of the
nucleotide sequences in (a), (b) or (c) above.

10 21. An isolated nucleic acid molecule comprising a
polynucleotide having a nucleotide sequence at least 90%
identical to a sequence selected from the group consisting
of:

(a) a nucleotide sequence encoding a polypeptide
15 comprising a portion of SEQ ID NOS:3 or 4, wherein said
portion lacks from 30 to 50 amino acids from the amino
terminus of said complete amino acid sequence as in SEQ ID
NO:3 or 4;

(b) a nucleotide sequence encoding a polypeptide
20 comprising a portion of amino acid sequence of SEQ ID NO: 3
or 4 wherein said portion lacks from 131 to 171 amino acids
from the carboxy-terminus of said complete amino acid
sequence as in SEQ ID NO:3 or 4; and

c) a nucleotide sequence encoding a polypeptide
25 comprising a portion of the amino acid sequence of SEQ ID
NO: 3 or 4 wherein said portion includes a combination of
any of the amino terminal and carboxy terminal deletions
according to (a) and (b), above.

30 22. A substantially pure polypeptide comprising
an amino acid sequence at least 70% identical to an amino
acid sequence selected from the group consisting of:

(a) the amino acid sequence of a full-length
polypeptide having the complete amino acid sequence as in

-81-

SEQ ID NO:3 or 4;

(b) the amino acid sequence comprising a portion of the complete amino acid sequence as in SEQ ID NO:3 or 4 wherein said portion lacks from 30-50 amino acids from the amino
5 terminus of said complete amino acid sequence.

(c) the amino acid sequence comprising a portion of the complete amino acid sequence as in SEQ ID NO:3 or 4 wherein said portion lacks from 131-171 amino acids from the carboxy-terminus of said complete amino acid sequence.

10 (d) the amino acid sequence comprising a portion of the complete amino acid sequence as in SEQ ID NO:3 or 4 wherein said portion is the result of a combination of any of the amino-terminal and carboxy-terminal deletions according to (b) and (c), above.

15

23. A method of treating obesity and diseases and disorders associated with obesity comprising administering to a patient in need thereof an effective amount of the
20 polypeptide as claimed in claim 22, or an antagonist thereof.

24. A chimeric protein comprising the polypeptide of Claim 22 fused to a heterologous polypeptide.

25

25. The chimeric protein of Claim 24 in which the heterologous polypeptide is a constant region of an immunoglobulin.

30 26. A pharmaceutical formulation containing as an active ingredient a composition as claimed in Claim 4 or 12.

-82-

27. Method of treating obesity or obesity related diseases by administering a pharmaceutical formulation as claimed in Claim 26.

5 28. The use of a composition as claimed in Claim 4 or 12 for the manufacture of a medicament for the treatment of obesity and/or obesity- related disorders.

10 29. A pharmaceutical formulation adapted for the treatment of obesity and/or obesity- related disorders containing a composition as claimed in Claim 4 or 12.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|---|
| <p>(51) International Patent Classification ⁷ : C07K 14/715, C12N 15/12, 15/63, 15/67, 5/10, C12P 21/00, A61P 3/04, A61K 38/17</p> | <p>A2</p> | <p>(11) International Publication Number: WO 00/59942 (43) International Publication Date: 12 October 2000 (12.10.00)</p> |
| <p>(21) International Application Number: PCT/US00/06682 (22) International Filing Date: 22 March 2000 (22.03.00) (30) Priority Data: 60/127,667 2 April 1999 (02.04.99) US (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indi- anapolis, IN 46285 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): SU, Eric, Wen [CN/US]; 13447 Dunes Drive, Carmel, IN 46032 (US). WEI, Jian-Jun [CN/US]; 25 Cinder Road, Oaktree Village #1A, Edison, NJ 08820 (US). (74) Agents: PLANT, Thomas, G. et al.; Lilly Corporate Center, Indianapolis, IN 46285 (US).</p> | | <p>(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p> |
| <p>(54) Title: hOB-BP2h COMPOSITIONS, METHODS AND USES THEREOF</p> <p>(57) Abstract</p> <p>The present invention relates to at least one novel hOB-BP2h polypeptide, including isolated nucleic acids that encode at least one hOB-BP2h polypeptide, hOB-BP2h polypeptides, vectors, host cells, transgenics, chimerics, and methods of making and using thereof, as well as hOB-BP2h-specific antibodies and methods.</p> | | |

SEQUENCE LISTING

<110> Eli Lilly and Company

<120> hOB-BP2h COMPOSITIONS, METHODS AND USES THEREOF

<130> X12652

<140>

<141>

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 1536

<212> DNA

<213> Homo sapiens

<400> 1

```

atgctactgc cactgctgct gtcctcgctg ctgggcggggt cccaggctat ggatgggaga 60
ttctggatac gagtgcagga gtcagtgatg gtgccggagg gcctgtgcat ctctgtgccc 120
tgctctttct cctacccccg acaggactgg acagggtcta cccagctta tggctactgg 180
ttcaaagcag tgactgagac aaccaagggt gtcctgtggt ccacaaacca ccagagtcga 240
gaggtggaaa tgagcacccg gggccgattc cagctcactg gggatcccgc caaggggaac 300
tgctccttgg tgatcagaga cgcgcagatg caggatgagt cacagtactt ctttcgggtg 360
gagagaggaa gctatgtgag atataatttc atgaacgatg ggttctttct aaaagtaaca 420
gccctgactc agaagcctga tgtctacatc cccgagaccc tggagcccgg gcagccgggtg 480
acgggtcatct gtgtgtttaa ctgggccttt gaggaatgtc caccctcttc tttctcctgg 540
acggggggctg ccctctcctc ccaaggaacc aaaccaacga cctcccactt ctcagtgtctc 600
agcttcacgc ccagacccca ggaccacgac accgacctca cctgccatgt ggacttctcc 660
agaaaggggtg tgagcgcaca gaggaccgtc cgactccgtg tggcctatgc ccccagagac 720
cttggttatca gcatttcacg tgacaacacg ccagatcctc cagagaacct gagagtgatg 780
gtttcccaag caaacaggac agtcctggaa aaccttggga acggcacgtc tctcccagta 840
ctggagggcc aaagcctgtg cctgggtctgt gtcacacaca gcagccccc agccaggctg 900
agctggaccc agagggggaca ggttctgagc ccctcccagc cctcagaccc cggggctcctg 960
gagctgcctc gggttcaagt ggagcacgaa ggagagttca cctgccacgc tcggcaccca 1020
ctgggctccc agcacgtctc tctcagcctc tccgtgact ataagaaggg actcatctca 1080
acggcattct ccaatggagc gtttctggga atcggcatca cggctcttct tttcctctgc 1140
ctggccctga tcatcatgaa gattctaccg aagagacgga ctcagacaga aaccccaggg 1200
cccaggttct cccggcacag cagatcctg gattacatca atgtgggtccc gacggctggc 1260
cccctggctc agaagcggaa tcagaaagcc acaccaaaca gtcctcggac ccctcttcca 1320
ccaggtgtct cctcccaga atcaaagaag aaccagaaaa agcagtatca gttgcccagt 1380
ttcccagaac ccaaatcatc cactcaagcc ccagaatccc aggagagcca agaggagctc 1440
cattatgcca cgctcaactt cccaggcgtc agaccagggc ctgaggcccc gatgcccagg 1500
ggcacccagg cggattatgc agaagtcaag ttccaa 1536

```


WO 00/59942

PCT/US00/06682

<210> 2
<211> 1917
<212> DNA
<213> Homo sapiens

<400> 2
atgctactgc cactgctgct gtcctcgctg ctgggcgggt cccaggctat ggatgggaga 60
ttctggatac gactgcagga gtcagtgatg gtgccggagg gcctgtgcat ctctgtgccc 120
tgctctttct cctacccccg acaagactgg acaggggtcta cccagctta tggctactgg 180
ttcaaagcag tgactgagac aaccaagggt gtcctgtgg ccacaaacca ccagagtcga 240
gaggtggaaa tgagcaccgc gggccgattc cagctcactg gggatccgc caaggggaac 300
tgctccttgg tgatcagaga cgcgagatg caggatgagt cacagtactt ctttcgggtg 360
gagagaggaa gctatgtgag atataatttc atgaacgatg ggttctttct aaaagtaaca 420
gtgctcagct tcacgcccag accccaggac cacaacaccg acctcacctg ccatgtggac 480
ttctccagaa aggggtgtgag cgacagagg accgtccgac tccgtgtggc ctatgcccc 540
agagaccttg ttatcagcat ttcacgtgac aacacgccag ccctggagcc ccagccccag 600
ggaaatgtcc catacctgga agcccaaaaa ggccagttcc tgcggctcct ctgtgctgct 660
gacagccagc cccctgccac actgagctgg gtccctgcaga acagagtcct ctccctcgtcc 720
catecctggg gccctagacc cctggggctg gagctgcccg ggggtgaaggc tggggattca 780
gggcgctaca cctgccgagc ggagaacagg cttggctccc agcagcgagc cctggacctc 840
tctgtgcagt atcctccaga gaacctgaga gtgatgggtt cccaagcaaa caggacagtc 900
ctggaaaacc ttgggaacgg cacgtctctc ccagtactgg agggccaaag cctgtgcctg 960
gtctgtgtca cacacagcag cccccagcc aggctgagct ggaccagag gggacagggt 1020
ctgagccccct cccagccctc agacccccgg gtccctggagc tgcctcgggt tcaagtggag 1080
cacgaaggag agttcacctg ccacgctcgg caccactgg gctcccagca cgtctctctc 1140
agcctctccg tgcactactc cccgaagctg ctggggcccct cctgctcctg ggaggctgag 1200
ggctctgact gcagctgctc ctcccaggcc agcccggccc cctctctgct ctggtggctt 1260
ggggaggagc tgctggaggg gaacagcagc caggactcct tcgaggtcac cccagctca 1320
gccgggccct gggccaacag ctccctgagc ctccatggag ggctcagctc cggcctcagg 1380
ctccgctgtg aggcctggaa cgtccatggg gccagagtg gatccatcct gcagctgcca 1440
gataagaagg gactcatctc aacggcattc tccaacggag cgtttctggg aatcggcatc 1500
acggctcttc ttttctctg cctggccctg atcatcatga agattctacc gaagagacgg 1560
actcagacag aaaccccgag gccaggttc tcccggcaca gcacgaccc ggattacatc 1620
aatgtgggtc cgacggctgg cccctgggt cagaagcgga atcagaaagc cacaccaaac 1680
agtctcggga cccctcttcc accaggtgct cctccccag aatcaaagaa gaaccagaaa 1740
aagcagtatc agttgcccag tttccagaa cccaaatcat cactcaagc cccagaatcc 1800
caggagagcc aagaggagct ccattatgcc acgtcaact tcccaggcgt cagacccagg 1860
cctgaggccc ggatgcccga gggcaccag gcggattatg cagaagtcaa gttccaa 1917

<210> 3
<211> 512
<212> PRT
<213> Homo sapiens

<400> 3
Met Leu Leu Pro Leu Leu Leu Ser Ser Leu Leu Gly Gly Ser Gln Ala

1 5 10 15
 Met Asp Gly Arg Phe Trp Ile Arg Val Gln Glu Ser Val Met Val Pro
 20 25 30
 Glu Gly Leu Cys Ile Ser Val Pro Cys Ser Phe Ser Tyr Pro Arg Gln
 35 40 45
 Asp Trp Thr Gly Ser Thr Pro Ala Tyr Gly Tyr Trp Phe Lys Ala Val
 50 55 60
 Thr Glu Thr Thr Lys Gly Ala Pro Val Ala Thr Asn His Gln Ser Arg
 65 70 75 80
 Glu Val Glu Met Ser Thr Arg Gly Arg Phe Gln Leu Thr Gly Asp Pro
 85 90 95
 Ala Lys Gly Asn Cys Ser Leu Val Ile Arg Asp Ala Gln Met Gln Asp
 100 105 110
 Glu Ser Gln Tyr Phe Phe Arg Val Glu Arg Gly Ser Tyr Val Arg Tyr
 115 120 125
 Asn Phe Met Asn Asp Gly Phe Phe Leu Lys Val Thr Ala Leu Thr Gln
 130 135 140
 Lys Pro Asp Val Tyr Ile Pro Glu Thr Leu Glu Pro Gly Gln Pro Val
 145 150 155 160
 Thr Val Ile Cys Val Phe Asn Trp Ala Phe Glu Glu Cys Pro Pro Pro
 165 170 175
 Ser Phe Ser Trp Thr Gly Ala Ala Leu Ser Ser Gln Gly Thr Lys Pro
 180 185 190
 Thr Thr Ser His Phe Ser Val Leu Ser Phe Thr Pro Arg Pro Gln Asp
 195 200 205
 His Asp Thr Asp Leu Thr Cys His Val Asp Phe Ser Arg Lys Gly Val
 210 215 220
 Ser Ala Gln Arg Thr Val Arg Leu Arg Val Ala Tyr Ala Pro Arg Asp
 225 230 235 240
 Leu Val Ile Ser Ile Ser Arg Asp Asn Thr Pro Asp Pro Pro Glu Asn
 245 250 255
 Leu Arg Val Met Val Ser Gln Ala Asn Arg Thr Val Leu Glu Asn Leu

| | | |
|---|-----|-----|
| 260 | 265 | 270 |
| Gly Asn Gly Thr Ser Leu Pro Val Leu Glu Gly Gln Ser Leu Cys Leu | | |
| 275 | 280 | 285 |
| Val Cys Val Thr His Ser Ser Pro Pro Ala Arg Leu Ser Trp Thr Gln | | |
| 290 | 295 | 300 |
| Arg Gly Gln Val Leu Ser Pro Ser Gln Pro Ser Asp Pro Gly Val Leu | | |
| 305 | 310 | 315 |
| Glu Leu Pro Arg Val Gln Val Glu His Glu Gly Glu Phe Thr Cys His | | |
| 325 | 330 | 335 |
| Ala Arg His Pro Leu Gly Ser Gln His Val Ser Leu Ser Leu Ser Val | | |
| 340 | 345 | 350 |
| His Tyr Lys Lys Gly Leu Ile Ser Thr Ala Phe Ser Asn Gly Ala Phe | | |
| 355 | 360 | 365 |
| Leu Gly Ile Gly Ile Thr Ala Leu Leu Phe Leu Cys Leu Ala Leu Ile | | |
| 370 | 375 | 380 |
| Ile Met Lys Ile Leu Pro Lys Arg Arg Thr Gln Thr Glu Thr Pro Arg | | |
| 385 | 390 | 395 |
| Pro Arg Phe Ser Arg His Ser Thr Ile Leu Asp Tyr Ile Asn Val Val | | |
| 405 | 410 | 415 |
| Pro Thr Ala Gly Pro Leu Ala Gln Lys Arg Asn Gln Lys Ala Thr Pro | | |
| 420 | 425 | 430 |
| Asn Ser Pro Arg Thr Pro Leu Pro Pro Gly Ala Pro Ser Pro Glu Ser | | |
| 435 | 440 | 445 |
| Lys Lys Asn Gln Lys Lys Gln Tyr Gln Leu Pro Ser Phe Pro Glu Pro | | |
| 450 | 455 | 460 |
| Lys Ser Ser Thr Gln Ala Pro Glu Ser Gln Glu Ser Gln Glu Glu Leu | | |
| 465 | 470 | 475 |
| His Tyr Ala Thr Leu Asn Phe Pro Gly Val Arg Pro Arg Pro Glu Ala | | |
| 485 | 490 | 495 |
| Arg Met Pro Lys Gly Thr Gln Ala Asp Tyr Ala Glu Val Lys Phe Gln | | |
| 500 | 505 | 510 |

<210> 4

<211> 639

<212> PRT

<213> Homo sapiens

<400> 4

Met Leu Leu Pro Leu Leu Ser Ser Leu Leu Gly Gly Ser Gln Ala
 1 5 10 15

Met Asp Gly Arg Phe Trp Ile Arg Val Gln Glu Ser Val Met Val Pro
 20 25 30

Glu Gly Leu Cys Ile Ser Val Pro Cys Ser Phe Ser Tyr Pro Arg Gln
 35 40 45

Asp Trp Thr Gly Ser Thr Pro Ala Tyr Gly Tyr Trp Phe Lys Ala Val
 50 55 60

Thr Glu Thr Thr Lys Gly Ala Pro Val Ala Thr Asn His Gln Ser Arg
 65 70 75 80

Glu Val Glu Met Ser Thr Arg Gly Arg Phe Gln Leu Thr Gly Asp Pro
 85 90 95

Ala Lys Gly Asn Cys Ser Leu Val Ile Arg Asp Ala Gln Met Gln Asp
 100 105 110

Glu Ser Gln Tyr Phe Phe Arg Val Glu Arg Gly Ser Tyr Val Arg Tyr
 115 120 125

Asn Phe Met Asn Asp Gly Phe Phe Leu Lys Val Thr Val Leu Ser Phe
 130 135 140

Thr Pro Arg Pro Gln Asp His Asn Thr Asp Leu Thr Cys His Val Asp
 145 150 155 160

Phe Ser Arg Lys Gly Val Ser Ala Gln Arg Thr Val Arg Leu Arg Val
 165 170 175

Ala Tyr Ala Pro Arg Asp Leu Val Ile Ser Ile Ser Arg Asp Asn Thr
 180 185 190

Pro Ala Leu Glu Pro Gln Pro Gln Gly Asn Val Pro Tyr Leu Glu Ala
 195 200 205

Gln Lys Gly Gln Phe Leu Arg Leu Leu Cys Ala Ala Asp Ser Gln Pro
 210 215 220

Pro Ala Thr Leu Ser Trp Val Leu Gln Asn Arg Val Leu Ser Ser Ser
 225 230 235 240

His Pro Trp Gly Pro Arg Pro Leu Gly Leu Glu Leu Pro Gly Val Lys
 245 250 255

Ala Gly Asp Ser Gly Arg Tyr Thr Cys Arg Ala Glu Asn Arg Leu Gly
 260 265 270

Ser Gln Gln Arg Ala Leu Asp Leu Ser Val Gln Tyr Pro Pro Glu Asn
 275 280 285

Leu Arg Val Met Val Ser Gln Ala Asn Arg Thr Val Leu Glu Asn Leu
 290 295 300

Gly Asn Gly Thr Ser Leu Pro Val Leu Glu Gly Gln Ser Leu Cys Leu
 305 310 315 320

Val Cys Val Thr His Ser Ser Pro Pro Ala Arg Leu Ser Trp Thr Gln
 325 330 335

Arg Gly Gln Val Leu Ser Pro Ser Gln Pro Ser Asp Pro Gly Val Leu
 340 345 350

Glu Leu Pro Arg Val Gln Val Glu His Glu Gly Glu Phe Thr Cys His
 355 360 365

Ala Arg His Pro Leu Gly Ser Gln His Val Ser Leu Ser Leu Ser Val
 370 375 380

His Tyr Ser Pro Lys Leu Leu Gly Pro Ser Cys Ser Trp Glu Ala Glu
 385 390 395 400

Gly Leu His Cys Ser Cys Ser Ser Gln Ala Ser Pro Ala Pro Ser Leu
 405 410 415

Arg Trp Trp Leu Gly Glu Glu Leu Leu Glu Gly Asn Ser Ser Gln Asp
 420 425 430

Ser Phe Glu Val Thr Pro Ser Ser Ala Gly Pro Trp Ala Asn Ser Ser
 435 440 445

Leu Ser Leu His Gly Gly Leu Ser Ser Gly Leu Arg Leu Arg Cys Glu
 450 455 460

WO 00/59942

PCT/US00/06682

Ala Trp Asn Val His Gly Ala Gln Ser Gly Ser Ile Leu Gln Leu Pro
465 470 475 480

Asp Lys Lys Gly Leu Ile Ser Thr Ala Phe Ser Asn Gly Ala Phe Leu
485 490 495

Gly Ile Gly Ile Thr Ala Leu Leu Phe Leu Cys Leu Ala Leu Ile Ile
500 505 510

Met Lys Ile Leu Pro Lys Arg Arg Thr Gln Thr Glu Thr Pro Arg Pro
515 520 525

Arg Phe Ser Arg His Ser Thr Ile Leu Asp Tyr Ile Asn Val Val Pro
530 535 540

Thr Ala Gly Pro Leu Ala Gln Lys Arg Asn Gln Lys Ala Thr Pro Asn
545 550 555 560

Ser Pro Arg Thr Pro Leu Pro Pro Gly Ala Pro Ser Pro Glu Ser Lys
565 570 575

Lys Asn Gln Lys Lys Gln Tyr Gln Leu Pro Ser Phe Pro Glu Pro Lys
580 585 590

Ser Ser Thr Gln Ala Pro Glu Ser Gln Glu Ser Gln Glu Glu Leu His
595 600 605

Tyr Ala Thr Leu Asn Phe Pro Gly Val Arg Pro Arg Pro Glu Ala Arg
610 615 620

Met Pro Lys Gly Thr Gln Ala Asp Tyr Ala Glu Val Lys Phe Gln
625 630 635

<210> 5

<211> 58

<212> PRT

<213> Homo sapiens

<400> 5

Ala Leu Thr Gln Lys Pro Asp Val Tyr Ile Pro Glu Thr Leu Glu Pro
1 5 10 15

Gly Gln Pro Val Thr Val Ile Cys Val Phe Asn Trp Ala Phe Glu Glu
20 25 30

Cys Pro Pro Pro Ser Phe Ser Trp Thr Gly Ala Ala Leu Ser Ser Gln
35 40 45

WO 00/59942

PCT/US00/06682


Gly Thr Lys Pro Thr Thr Ser His Phe Ser
50 55

Please type a plus sign (+) inside this box



PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION

☐
☒

Declaration Submitted with Initial Filing
Declaration Submitted after Initial Filing

| | |
|------------------------|---------------------|
| Attorney Docket Number | X-12652 |
| First Named Inventor | Eric Wen Su, et al. |
| COMPLETE IF KNOWN | |
| Application Number | |
| Filing Date | |
| Group Art Unit | |
| Examiner Name | |

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

HOB-BP2h COMPOSITIONS, METHODS AND USES THEREOF

the specification of which

☐ is attached hereto

OR

☒ was filed on
(MM/DD/YYYY)

03/22/2000

as United States Application Number or PCT International

Application
Number

PCT/US00/06682

and was amended on
(MM/DD/YYYY)

(if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

| Prior Foreign Application Number(s) | Country | Foreign Filing Date (MM/DD/YYYY) | Priority Not Claimed | Certified Copy Attached | |
|--|---------|-------------------------------------|--------------------------|--------------------------|--------------------------|
| | | | | YES | NO |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| | | | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto:

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional applications(s) listed below.

| Application Number(s) | Filing Date (MM/DD/YYYY) | <input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority sheet attached hereto. |
|-----------------------|--------------------------|--|
| 60/127,667 | 04/02/1999 | |

Please type a plus sign (+) inside this box



PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE**DECLARATION**

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

| U.S. Parent Application Number | PCT Parent Number | Parent Filing Date (MM/DD/YYYY) | Parent Patent Number (if applicable) |
|-----------------------------------|----------------------|------------------------------------|---|
| | | | |

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

| Attorney Name | Reg. No. |
|----------------------|----------|
| Arvie J. Anderson | 45,263 |
| Lynn D. Apelgren | 45,341 |
| Robert A. Armitage | 27,417 |
| Brian P. Barrett | 39,597 |
| Michael T. Bates | 34,121 |
| Roger S. Benjamin | 27,025 |
| Gary M. Birch | P48,881 |
| William R. Boudreaux | 35,796 |
| Steven P. Caltrider | 36,467 |
| Paul R. Cantrell | 36,470 |
| Charles E. Cohen | 34,565 |
| Donald L. Corneglio | 30,741 |
| Gregory A. Cox | 47,504 |
| Paula K. Davis | 47,517 |
| Elizabeth A. Dawalt | 44,646 |
| John C. Demeter | 30,167 |
| Manisha A. Desai | 43,585 |
| Joanne Longo Feeney | 35,134 |
| Paul J. Gaylo | 36,808 |
| Francis O. Ginah | 44,712 |
| Janet A. Gongola | P48,436 |
| Amy E. Hamilton | 33,894 |
| Frederick D. Hunter | 26,915 |
| Thomas E. Jackson | 33,064 |
| Charles Joyner | 30,466 |
| Gerald P. Keleher | 43,707 |

| Attorney Name | Reg. No. |
|------------------------|----------|
| James J. Kelley | 41,888 |
| Paul J. Kovuniemi | 31,533 |
| Robert E. Lee | 27,919 |
| Kirby Lee | 47,744 |
| James P. Leeds | 35,241 |
| Nelsen L. Lentz | 38,537 |
| Douglas K. Norman | 33,267 |
| Arleen Palmberg | 40,422 |
| Thomas G. Plant | 35,784 |
| Edward Prein | 37,212 |
| Grant E. Reed | 41,264 |
| James J. Sales | 33,773 |
| Michael J. Sayles | 32,295 |
| Robert L. Sharp | 45,609 |
| David M. Stemerick | 40,187 |
| Mark J. Stewart | 43,936 |
| Robert D. Titus | 40,206 |
| Robert C. Tucker | 45,165 |
| Tina M. Tucker | 47,145 |
| MaChari Vorndran-Jones | 36,711 |
| Gilbert T. Voy | 43,972 |
| Thomas D. Webster | 39,872 |
| Lawrence T. Welch | 29,487 |
| Alexander Wilson | 45,782 |
| Dan L. Wood | P48,613 |

☐ Additional registered practitioner(s) named on a supplemental sheet attached hereto.

Direct all correspondence to:

Name **ELI LILLY AND COMPANY**Address **ATTN: Robert Sharp**Address **LILLY CORPORATE CENTER/DC1104**City **INDIANAPOLIS** State **INDIANA**ZIP **46285**Country Telephone **(317) 276-5332** Fax **(317) 276-3861**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A Petition has been filed for this unsigned inventorGiven Name **Eric**Middle Name **Wen**Family Name **Su**Suffix
e.g. Jr.

Inventor's Signature

Eric Wen Su

Date

*10/9/01*Residence: City **Carmel**State **IN**Country **US**Citizenship **US**Address **13447 Dunes Drive**Post Office Address **SAME AS ABOVE**City **Carmel**State **IN**

Zip

46032

Country

US

☒ Additional Inventors are being named on supplement sheet(s) attached hereto.


09/29/10 10:00:00

Please type a plus sign (+) inside this box ☐

PTO/SB/01 (8-96) (MODIFIED)

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

DECLARATION

| | | | | | | | |
|--|---|-------|-------------|---|-------------|----------|-----------------|
| Name of Additional Joint Inventor, if any: | | | | <input type="checkbox"/> A Petition has been filed for this unsigned inventor | | | |
| Given Name | Wei | | Middle Name | | Family Name | Jian-Jun | Suffix e.g. Jr. |
| Inventor's Signature |  | | | | | Date | 09/29/10 |
| Residence: City | Edison | NJ | State | | Country | US | Citizenship CN |
| Address | 25 Cinder Road, Oaktree Village #1A | | | | | | |
| Post Office Address | SAME AS ABOVE | | | | | | |
| City | Edison | State | | Zip | 08820 | Country | US |